Risk factors and costs of developing surgical site infection after primary hip arthroplasty in Norway by Cheng, Mengyuan
  
 
 
Risk factors and costs of developing 
surgical site infection after primary 
hip arthroplasty in Norway 
 
Mengyuan Cheng 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Master Thesis 
Department of Health Management and Health Economics 
Faculty of Medicine 
 
University of Oslo 
 
August 2015
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Mengyuan Cheng  
2015  
Risk factors and costs of developing surgical site infection after primary hip arthroplasty 
in Norway  
https://www.duo.uio.no/ 
University of Oslo 
ii 
 
Preface 
This document is a master thesis for the degree of Master of Philosophy (M. Phil.) in Health 
economics, policy and management at the University of Oslo. It was developed during my 
internship at the Norwegian Institute of Public Health (NIPH).  Register data from the 
Norwegian Surveillance System for Antibiotic Consumption and Healthcare-Associated 
Infections (NOIS) were provided by NIPH while clinical experts provided data on clinical 
management of surgical site infection. Unfortunately, we received response from only one 
of the experts that were invited to provide data despite of two reminders. The work was 
undertaken with keen support from employees at NIPH that offered a working area and 
access to computer facilities for the data files.  
I am very grateful for the opportunity offered by NIPH and I would like to thank my 
supervisor Professor Ivar Sønbø Kristiansen for his guidance and support throughout the 
writing of the thesis and supervisor Hanna Merete Eriksen for always giving enlightening 
advice and positive feedbacks.  
  
iii 
 
Abstract 
Background A patient who developed a surgical site infection (SSI) after hip arthroplasty 
was likely to having an extended length of stay in hospital and incurring additional costs 
in terms of bed-days, diagnostic and therapeutic interventions, etc. It would be important 
to identify any patient-, surgical- and hospital-related factors that could be modified 
before surgery to control and decrease the risk of post-operative infection. 
Aim Identify the risk factors for SSI after primary hip arthroplasty, as well as to estimate 
the hospital cost of SSI in Norway. 
Method Risk factor analysis was a register based retrospective cohort study at the 
national level in Norway including patients undergoing hip arthroplasty between 
September 2012 and December 2014. Binary logistic regression models were constructed 
for assessing relationships between the outcome variable (SSI) and a series of explanatory 
variables. For cost analysis, a bottom-up approach was adopted. Health care resources 
utilized for SSI treatment and the quantities of these resources were derived from an 
expert survey. Unit costs for the resources were obtained from various sources, including 
Diagnosis Related Groups (DRG) price list, the Norwegian Medicines Agency database, etc. 
Total cost of SSI was then calculated by multiplying the quantities of resource use (q) by 
the unit costs (p) of the resources. 
Result During the study period, 17,762 total hip arthroplasty operations and 7,334 
hemiarthroplasty procedures were registered in the NOIS. The incidence of SSI after THA 
was 2.2% (390 of 17,762) and that after HA was 3.6% (264 of 7,334). According to the 
multivariate regression model, the risk factors for SSI after THA were age, male sex, ASA 
score ≥ III, surgery lasting more than 120 minutes, elective surgery, cement-less fixation 
and post-operative hospital stay. Perioperative antibiotic prophylaxis and specialty 
hospital were associated with lower risk of SSI. For HA, the risk factors were fewer, 
including male sex, cement-less fixation and post-operative hospital stay. 
The average cost of a SSI after primary hip arthroplasty for hospital was NOK 198,121. 
The main cost drivers were readmission stay (56%), followed by reoperation (28%) and 
additional LOS (11%). 
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Conclusion Of all the risk factors detected in this study, cemented prosthesis and 
perioperative antibiotic prophylaxis are the modifiable ones and therefore recommended 
to orthopedic surgeon and infection control personnel for controlling and reducing SSIs 
following THA. Given these two are common practice in Norway, further studies could 
focus on including more explanatory variables in risk analysis or on analyzing the effect 
of various parameters of perioperative antibiotic prophylaxis and cement fixation (such 
as the time, route and dosage of administration) to establish more effective preventive 
interventions. 
Surgical site infection following primary hip arthroplasty causes significant economic 
burden for Norwegian hospitals, mainly due to substantial increase in hospital stay and 
the resource demanding nature of its revision procedures. The high cost of SSI implies 
that substantial cost savings can be achieved by reducing the number of SSIs, and in turn, 
highlights the importance of detecting modifiable risk factors for SSI.  
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1   Introduction  
Surgical site infection following primary hip arthroplasty is one of the severe complications 
that could lead to increased morbidity, mortality and high cost (C. Edwards, A. Counsell, C. 
Boulton, & Moran, 2008; Coello et al., 2005). It is very important that surgeons as well as 
infection control personnel are able to identify potential risk factors for developing SSI and 
implement preventive measures accordingly. 
Coello and co-workers (Coello et al., 2005) investigated the adverse impact of SSI for nine 
defined categories of surgery, including limb amputation, small/large bowel surgery, vascular 
surgery, coronary artery bypass graft, hip prosthesis, knee prosthesis, open reduction of long 
bone fracture and abdominal hysterectomy, in English hospitals and found the impacts differed 
greatly across categories. This highlighted the importance of measuring the impact for 
individual category rather than for all SSIs and all surgical procedures. 
Whilst some studies about the impact of surgical site infection following primary hip 
arthroplasty have been conducted, little work exists providing an economic perspective. This 
thesis contributes to knowledge by analyzing risk factors for and resource consequences of SSI, 
in order to identify target areas for infection prevention and by that the cost of SSI. These results 
can also be used to inform subsequent cost-effectiveness analyses that evaluate the efficiency 
of interventions to reduce the risk of SSIs. 
2   Background 
As showed in Figure 1, a hip joint is a “ball-and-socket” joint where the ball is the femoral head 
and the socket is a "cup-shaped" component of the pelvis called the acetabulum, uniting two 
separate bones: the femur (also known as thighbone) and the pelvis. As in all the other joints, 
between the acetabular cup and the femoral head there exists a cartilage to lubricate their 
movement and facilitate the articulation (Rabiei, 2009). The primary purposes of hip joints are 
to support the weight of upper body during standing, walking or running, and help with body 
movements like stretching and bending. 
2 
 
 
Figure 1  Illustration of the anatomy of hip joint (Source: Medical Multimedia, www. 
medicalmultimediagroup.com) 
When the natural hip joints are impaired and cause persistent pain or problems with daily 
activity due to reasons like osteoarthritis (cartilage inside hip joints becomes worn away), hip 
fracture, rheumatoid arthritis (body immune system attacks the lining of hip joints), etc., it 
might be necessary for the patients to have a hip arthroplasty.  
Hip arthroplasty (used synonymously for hip replacement in this study) is an orthopedic surgery 
where the damaged parts of hip joint being removed and replaced by artificial ones (known as 
prosthesis) to relieve pain and restore mobility. This reconstructive procedure, which can be 
either total hip arthroplasty (THA) or a hemiarthroplasty (HA), has improved the management 
of those hip joint diseases that have responded poorly to conventional medical therapy (Rabiei, 
2009).  
As a surgery that usually carried out in older adults, the number of hip arthroplasty done will 
increase as population is aging. Kurtz and colleagues (Kurtz, Ong, Lau, Mowat, & Halpern, 
2007) reported a projected increase in THA numbers of 174% to 600,000 procedures per year 
in the United States from 2005 to 2030. In Norway, each year there are more than 10,000 people 
having their hip joints replaced, entirely or partly (N. A. Register, 2015). The problem of 
osteoporosis and other hip joint diseases that require hip arthroplasty is likely to be a growing 
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burden to society in the near future as life expectancy in Norway is still increasing and the 
absolute number of older persons at risk of damaging hip joint is expected to increase.  
2.1 Total hip arthroplasty (THA)  
Figure 2 Anteroposterior pelvic radiograph for a patient who had metal-on-metal total hip 
arthroplasty (Williams, Greidanus, Masri, Duncan, & Garbuz, 2011) 
A total hip arthroplasty involves the femoral component fitting into the top of the femur to 
replace the ball of the ball-and-socket joint, and the acetabular cup sitting in the pelvis to replace 
the socket. Since its introduction in the 1960s, total hip arthroplasty has become one of the most 
successful and frequently undertaken elective surgeries with a dramatically improvement in 
function restoring and a great degree of patient satisfaction (Ackerman, Graves, Bennell, & 
Osborne, 2006). After reviewing twenty-six studies on total hip arthroplasty, Ethgen and 
coworkers (Ethgen, Bruyère, Richy, Dardennes, & Reginster, 2004) concluded that total hip 
arthroplasty was effective in terms of improvement in health-related quality-of-life dimensions, 
with the occasional exception of the social dimension.  
The demand for THAs has been increasing in the last two decades. According to the Norwegian 
Arthroplasty Register (N. A. Register, 2015), the number of primary THAs performed in 
Norway has increased from 4606 in 1994 to 8099 in 2014. 
 
4 
 
 
2.2 Hemiarthroplasty  
Figure 3 X-ray of a patient who had a unipolar hemiarthroplasty (Cash, Bayer, Logan, & 
Wimhurst, 2010).  
This anteroposterior radiograph shows the femoral component (Exeter Trauma Stem) and the 
normal, native acetabulum. 
Different from THR, a HA involves only the prosthesis replacement of femoral part of the hip 
joint. The most common reason for HA is hip fracture. In Norway, HA due to hip fractures 
should be reported to the Norwegian Hip Fracture Register (NHFR). In 2014, the number of 
hip fractures reported in NHFR decreased slightly from 9284 to 8956 (N. A. Register, 2015). 
Meanwhile more and more dislocated fractures were treated with hemiarthroplasty since 2005 
(Figure 4). 
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Figure 4 Percentage of displaced intracapsular fractures treated with two screws or sticks, or a 
unipolar or bipolar hemi prosthesis according to the Norwegian Hip Fracture Register (T. N. A. 
Register, 2010) 
2.3 Revision after primary hip arthroplasty 
Revision after primary hip arthroplasty is defined as a surgical procedure that involves 
exchange or removal of prosthesis. According to the Norwegian Arthroplasty Register (N. A. 
Register, 2015), for patients had revision procedures in 2014, the most common cause for 
revision surgery was acetabular loosening (24%), followed by femoral loosening (16%), deep 
infection (15%) and dislocation (12%). Deep infection has since 2010 exceeded dislocation to 
be the third most common reason for revision.  
2.4 Surgical site infection after primary hip prosthesis  
Hip replacement surgery, like other surgical procedures, carries a risk of complications. The 
most common complications after primary hip prosthesis are instability, aseptic loosening, 
periprosthetic fracture, infection, and occasionally death. While total hip arthroplasty has 
progressed to become one of the most successful surgical procedures, infection remains a 
serious and common complication (Senthi, Munro, & Pitto, 2011). In a recent point-prevalence 
survey of inpatients conducted in the US (Magill et al., 2014), surgical site infection, which 
accounted for 21.8% of reported infection, was identified as the most frequently occurring 
healthcare-associated infection (HCAI) along with pneumonia infection. A study (Dale et al., 
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2012) based on the Nordic Arthroplasty Register Association (NARA) dataset from 1995 to 
2009 reported that 0.6% of the primary THAs were revised due to infection during that period. 
In addition, compared with the period 1995-1999, the relative risks of revision due to infection 
in 2000-2004 and 2005-2009 increased from 1.1 to 1.6 in four countries (Denmark, Finland, 
Norway and Sweden) and this risk increasing confirmed the earlier findings from Norway 
(Dale, Hallan, Espehaug, Havelin, & Engesæter, 2009). 
2.4.1 Surgical site infection  
Infection could be defined as “invasion and multiplication of microorganisms in body tissues, 
causing cellular injury and inflammatory response” (Dale, 2013). Though different publications 
use different criteria for surgical site infection, the most commonly used ones are the Centers 
of Disease Control and Prevention (CDC)’s criteria for postoperative SSI. The CDC criteria 
divides SSIs into incisional SSIs, which are further classified as superficial incision SSIs, deep 
incision SSIs, and organ/space SSIs for surveillance classification purpose (Teresa C. Horan et 
al., 1992). The CDC definitions (Table 1) of SSIs have been applied consistently by 
surveillance and surgical personnel in many settings and currently are a de facto international 
standard (Løwer, Eriksen, Aavitsland, & Skjeldestad, 2013; Teresa C. Horan et al., 1992). 
Table 1 CDC definitions of SSIs (Teresa C. Horan et al., 1992) 
Superficial 
infection 
Occurs within 30 days of surgery, involves only skin and subcutaneous tissue and meets at 
least one of the following criteria: 
 
 1. Purulent drainage from superficial incision 
 2. Organisms are grown and pus cells seen from aseptically obtained swab/tissue from the 
superficial incision  
 3. At least one of the following symptoms or signs: pain or tenderness, localized swelling, 
redness or heat, and a) the clinician diagnoses an infection or b) the superficial incision is 
deliberately opened by a surgeon to manage the infection, unless the incision is culture-
negative. 
 
 
 
Deep infection Occurs within 30 days (no implant) or one year (implant) of surgery, involves deep fascia and 
muscle layers and appears to be related to the procedure and meets at least one of the 
following criteria: 
 
 
 1. Purulent drainage from the deep tissue but not the joint or bone 
 2. Organisms are grown and pus cells seen from aseptically obtained swab/tissue from the 
deep incision  
 
3. A deep incision which spontaneously dehisces or is opened by the surgeon when the 
patient has fever (> 38˚C), localized pain or tenderness, unless the incision is culture-negative 
 
 
 4. An abscess or other evidence of deep infection found during re-operation, or by 
histopathological or radiological examination   
Organ/Space 
infection 
Occurs within 30 days (no implant) or one year (implant) after surgery. Involves joint and/or 
bone related to the site of the operation with any other tissues. 
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 Appears to be related to the procedure and meets at least one of the following criteria:  
 1. Purulent drainage from a drain which is placed through a stab incision into the joint  
 2. Organisms are grown and pus cells seen from aseptically obtained swab/tissue from the 
joint/bone  
 3. An abscess or other evidence of joint/bone infection found during re-operation, or by 
histopathological or radiological examination  
 4. The patient has at least two of the following signs or symptoms with no other recognized 
cause: joint pain, swelling, tenderness, heat, evidence of effusion or limitation of movement 
and at least one of the following: 
 
 
 a) Organisms and white blood cells seen on Gram stain of the joint 
 b) Positive antigen test on blood, urine, or joint fluid 
 c) Cellular profile and chemistry of joint fluid compatible with infection and not explained by 
an underlying rheumatological disorder  
 d) Radiological evidence of infection, e.g. abnormal findings on radiographs, CT scans, MRI, 
radiolabeled scan (gallium, technetium, etc.)   
 
SSIs have been reported to occur in 0.5% - 2.5% of primary total hip arthroplasty, and estimates 
vary across countries due to different surveillance or register methods, study periods, patient 
demographics and of course difference in the risk of SSI (Merollini, Crawford, & Graves, 2013; 
Namba, Inacio, & Paxton, 2012 October; S. Ridgeway et al., 2005; Vicente Monge Jodra , 
Lourdes Sainz de los Terreros Soler , Cristina Díaz‐Agero Pérez , Carmen María Saa Requejo 
, & Nieves Plana Farrás 2006). 
Not only resulting in increased morbidity, mortality (Awad, August 2012) and reduced 
functional outcomes in patients, SSIs also impose a considerable economic burden to patients 
and their families by prolonging the duration of hospital stay, causing additional surgery and 
increasing costs (Broex, van Asselt, Bruggeman, & van Tiel, 2009; Chen, Chou, & Chou, 2005; 
Coello et al., 2005). 
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Figure 5 Cross-section of abdominal wall depicting CDC classifications of surgical site infection 
(Teresa C. Horan et al., 1992) 
2.4.2 Risk factors for SSI after THR/HA identified in literature 
Whether a wound becomes infected after surgery depends on a complex interaction between 
patient-related, surgical-related, and microbial-related factors. Optimal application of SSI 
prevention measures often requires targeting a variety of risk factors. In the context of SSI, the 
term risk factor refers to a variable that has a significant, independent association with the 
development of the infection (Alicia J. Mangram et al., 1999).  
A variety of risk factors for infection after THA and HA have been reported. A British study 
(S. Ridgeway et al., 2005) based on the Nosocomial Infection National Surveillance (NINS) 
service data found that age, female gender, American Society of Anesthesiologists (ASA) score, 
body mass index (BMI), trauma, duration of operation and pre-operative stay were significantly 
associated with the risk of SSI after THR while for HA, only ASA score and age were 
significant factors. The multivariate analysis identified age ≥ 80, trauma, duration of operation 
> 120 minutes and ASA score ≥ III as significant independent risk factors for SSI, regardless 
of the type of hip arthroplasty. These findings are in line with the reported results from a similar 
study (Namba et al., 2012 October) done in the US. In 2011, Dale and colleagues (Dale et al., 
2011) assessed the risk factors for infection after hip arthroplasty using data from the 
Norwegian Arthroplasty Register (NAR), the Norwegian Hip Fracture Register (NHFR) and 
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the Norwegian Surveillance System for Antibiotic Consumption and Healthcare-Associated 
Infections (NOIS), and found advanced age, ASA class higher than II and short duration of 
surgery were risk factors for SSI after THA. 
2.4.3 Management of SSI  
Superficial SSIs usually do not have a big impact on patients’ quality of life and are typically 
treated with simple measures like superficial debridement, local drainage and oral antibiotics. 
Deep or organ/space infection, on the other hand, involves the muscle, fascial planes or organ, 
can have devastating consequences for the patients and typically require revision surgery, 
including one-stage exchange revision and two-stage exchange revision, or in the most severe 
cases permanent removal of the prosthesis (Resection procedure) (Urban, 2006). One-stage 
exchange is one surgery that involves both the extraction of prosthesis and implantation of a 
new prosthesis. While in two-stage exchange revision, the extraction and implantation are 
conducted separately in two surgeries where the new prosthesis is implanted in the second 
surgery 2 to 12 weeks after the first one. In the absence of a universally accepted protocol, the 
management of deep or organ/space SSIs is multidisciplinary and challenging; patients are 
generally managed on a case-by-case basis taking account of individual factors. A recent 
retrospective analysis conducted in Australia (Merollini et al., 2013) showed that the majority 
(74%) of patients experienced early infection onset were first treated with debridement, 
antibiotics and implant retention (DAIR). The following first treatments were one-stage 
revision and two-stage revision with 89.7% and 92.9% success rate respectively. A Swiss study 
(Betsch, Eggli, Siebenrock, Täuber, & Mühlemann, 2008), however, reported the most common 
treatment strategy to be two-stage revision (75%), followed by DAIR (17.6%) and one-stage 
revision (5.9%). Aside from Switzerland, 2-stage revision, the old golden standard in treating 
deep or organ/space SSIs, is also the preferred treatment in the US (Lentino, 2003). 
In Norway, about 50% of the revision surgeries reported in the National Arthroplasty Register 
(NAR) were debridement and retention of the infected implant, 25% were two-stage exchange, 
12% of one-stage exchange and the remaining 13% were resection arthroplasty (Girdlestone 
procedure). For patients who had poor health status or short life expectancy, long-term 
antimicrobial suppression was an alternative treatment to revision surgery. This procedure is 
not reported to NAR, so to what extent the long-term suppression is used in Norway remains 
unknown.  
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2.4.4 Economic burden of SSI  
A number of studies have been conducted to estimate the economic burden of SSI (Broex et al., 
2009; Jenks, Laurent, McQuarry, & Watkins, 2014; Urban, 2006). These researches revealed 
that patients with SSI often require longer time in hospital, more nursing care, additional 
diagnostic tests and, sometimes, revision surgery and readmission to hospital, thereby posing 
heavy economic burden to health care sector. The magnitude of the economic impact, however, 
varies widely across studies, mainly due to the inconsistency of study methods, cost 
components included, perspective adopted and hospital reimbursement systems. 
Katharina M.D. Merollini and colleagues conducted a retrospective analysis (Merollini et al., 
2013) in 2013 to estimate reimbursement costs of surgical site infections after hip arthroplasty 
in Australia. In this study, treatment costs were estimated based on Australian Refined 
Diagnosis Related Groups (AR-DRG) cost accounting codes assigned to each patient hospital 
episode. The authors found that patients who were first treated with debridement, antibiotics 
and implant retention (DAIR) had an average cost of AUD 13,187 (NOK 80,915), while those 
first treated with one-stage revision and two-stage revision had average costs of AUD 27,006 
(NOK 165,708) and 42,772 (NOK 262,447) respectively. Patients had excision arthroplasty on 
average costed AUD 23,805 (NOK 146,066). Overall, the total average treatment cost per deep 
SSI was AUD 24,644 (NOK 150,828) across all treatment modalities. 
A recent study from UK by P.J. Jenks and coworkers (Jenks et al., 2014) assessed the economic 
burden of SSI over a two-year period based on SSI surveillance data, patient level information 
and costing system dataset. The median additional length of stay (LOS) attributable to SSI 
reported in this study was 10 days (95% confidence interval (CI): 7-13 days); the median 
additional cost attributable to SSI was GBP 5,239 (NOK 67,113) across all categories, and GBP 
3,214 (NOK 41,172) (95% CI: 657-17,040) for hip replacement alone. After calculating the 
opportunity cost of eliminating all SSIs that occurred in the study period, the researchers found 
that for seven surgical categories, hip replacement included, the hospital would have been 
financially worse off by eliminating all SSIs. The authors concluded that the current system of 
reimbursement provided financial disincentive to SSI reduction. 
Another Australian study from 2013 by T.N. Peel and colleagues (Peel et al., 2013), on the 
other hand, examined the overall hospital cost of the treatment of prosthetic joint infection 
across 10 hospitals over a 3-year period. Cost calculations in this study included hospitalization 
costs, surgical costs, hospital-in-the-home costs and antibiotic therapy costs. Their findings 
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showed that the median cost of treating prosthetic joint infection was AUD 34,800 (NOK 
212,986). Aside from the cost estimating, the authors also modeled factors associated with the 
cost and found that compared to cost of DAIR, surgical treatment with one-stage exchange 
(100% increase; p = 0.009) or resection arthroplasty (48% increase; p = 0.001), among other 
factors, were independently associated with increased treatment costs. 
A review of cost analysis of surgical site infections by Joshua A. Urban (Urban, 2006) reported 
that the principal determinants of the SSI costs were the depth of the infection, geographic 
localization and the type of surgery performed. The costs increased with the depth of the 
infection. That was, the costs associated with superficial infections were relatively low, but 
increased with deep and, especially, organ/space infections.  
To date, the estimation of SSI cost in Norway has not been examined in great detail even though 
SSI has been recognized as a costly complication and the incidence rate in Norway has been 
increasing in recent years (Dale et al., 2009). 
2.5 The Norwegian Surveillance System for Antibiotic Consumption and 
Healthcare-Associated Infections (NOIS)  
The Norwegian Surveillance System for Antibiotic Consumption and Healthcare-Associated 
Infections (NOIS) was introduced in 2005 following a 2004 government strategy of reducing 
health care associated infections (Løwer et al., 2013). Due to its mandatory nature (95% 
participation rate in 2009), all patients who undergo at least one of the five specified surgical 
procedures (coronary artery bypass graft; cesarean section; primary hip prosthesis; 
cholecystectomy and colon surgery) at any Norwegian hospitals are supposed to be registered 
in the NOIS.  
At hospital level, data were collected before, during, and 30 days after surgery (Figure 6). For 
surgeries involve implant, the follow-up time is extended to one year. More specifically, basic 
patient information is collected at admission then surgery-related information collected during 
surgery, followed by patient’s infection status being registered by a physician at discharge. 
Then 25-30 days after surgery, patients are expected to receive a customized and personalized 
follow-up letter asking for infectious events. The letter contains questions about certain specific 
signs of SSI and whether the patient has consulted a doctor about these signs. Aside from the 
questions, the letter also contains classification guidance for doctors who diagnosed the 
infection (Berg et al., 2011). Reminders are sent to patients who did not respond to the 
questionnaire and finally, phone calls made to the remaining non-respondents. All SSIs, other 
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than superficial ones, that have been detected during hospitalization and after discharge are to 
be confirmed or diagnosed by a physician according to CDC definitions. Superficial infections 
could be patient reported and are coded separately in NOIS-SSI. 
 
Figure 6 Points in time for collection of information during 30-day follow-up in NOIS-SSI (Løwer 
et al., 2013) 
Up to 2009, 70% (Løwer et al., 2013) of hospitals in Norway have developed or acquired 
computerized infection control modules (ICMs) in order to harvest data from hospitals’ existing 
systems, initiate patient follow-up letters, establish quality assurance routines and generate 
statistics or reports for local use and submission of data to national level. Data collected in the 
NOIS encompasses background and explanatory variables (e.g. patient information, surgery 
details) and outcome variables (e.g. infection status, readmission). The former ones are almost 
all being collected by ICMs automatically while the later ones must be entered manually.  
After evaluating its first five years of operation H. L. Løwer and colleagues (Løwer et al., 2013) 
claimed that NOIS has achieved high hospital participation, a reasonable proportion of non-
missing variables and 90.7% completeness of 30-day patient follow-up. 
2.6 Aims and research questions 
The aim of this study is to identify risk factors for surgical site infection (SSI) following primary 
hip arthroplasty, as well as to estimate the costs of such infection for hospitals in Norway in 
order to identify target areas to reduce SSI and thereby the cost. The specific research questions 
were as follows: 
 What are the risk factors for SSI following THA and HA respectively? 
 What type of health care resources and what quantities are utilized in hospital for 
treating SSI after primary hip arthroplasty? 
 What is the economic burden and main cost drivers for SSI after primary hip 
arthroplasty for Norwegian hospitals?  
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following hypotheses were to be tested:  
 Age, ASA (the American Society of Anesthesiologists classification system for physical 
status) score, and prolonged duration of surgery are the most important factors 
associated with SSI 
 SSI following primary hip arthroplasty causes high additional costs for hospitals, mainly 
driven by prolonged hospitalization, additional diagnostic tests, therapeutic use of 
antibiotics and revision surgery  
3   Data and Methodology  
3.1 Data source 
Data used in this study came from various sources, including the Norwegian Surveillance 
System for Antibiotic Consumption and Healthcare-Associated Infections (NOIS), an expert 
survey, Diagnosis Related Group price list, the Norwegian Medicines Agency, etc. 
3.1.1 NOIS data 
All primary hip arthroplasty registered in the NOIS during September 2012 to December 2014 
were included in this study. The NOIS database contains extensive information on a multitude 
of subject areas, but important to this study are those listed in Table 2. 
Table 2 Central variables in the Norwegian Surveillance System for Antibiotic Consumption and 
Healthcare-Associated Infections (NOIS) dataset 
Variable Definition 
Patient   
  Age Age of patients 
  Sex Male/Female 
  ASA score 
Score of the six-category physical status classification system that adopted by the 
American Society of Anesthesiologists  
Surgery   
  Wound contamination Clean/Other (clean-contaminated, contaminated and dirty) 
  Duration of surgery Surgery time measured in minutes 
  NNIS risk index 
Patients are given a risk point if they have: surgery time over 75 percentile, 
contaminated or dirty wound or ASA score higher than 2 
  Perioperative antibiotic   
prophylaxis Perioperative prophylaxis used or not 
  Elective Elective or emergency surgery 
  Cement Cement used or not for prosthesis fixation 
  Pre-operation stay Days spent in hospital before surgery 
  Follow-up time Time of patient follow-up, ranging from 0 to 30 days 
Hospital   
  Region Health region* that a hospital belongs to  
14 
 
  Size The size of a hospital, measured by the number of hospital beds 
  Type 
The type of hospital, categorized based on the level of healthcare the hospital 
delivered  
Cost   
  Postoperative stay Days spent in hospital after surgery 
  Readmission due to 
infection Readmission to hospital due to SSI 
  Reoperation due to infection Reoperation due to SSI 
* Health region map has been attached as Appendix 1 
3.1.2 Expert survey 
The survey was designed to elicit clinical management of patients with different types of SSIs 
after total hip arthroplasty and hemiarthroplasty in Norway. Four orthopedic surgeons working 
in the four health regions in Norway were chosen as experts from the NOIS reference group. 
An electronic survey (see Appendix 2-5) was sent to the experts by e-mail during the research 
period. One of the selected surgeons responded after the first contact while the others did not. 
Therefore, shortly after the first contact, another two follow-up e-mails were sent out to the 
non-respondents as reminders, but regrettably, the other three experts had not replied to the 
survey throughout the whole research period (10 weeks).   
In the survey, healthcare resources utilized for the treatment of SSI were listed according to 
infection severity and experts were asked to identify relevant resource items and to estimate the 
quantity of each healthcare resource item used based on their empirical experience.  
3.1.3 Unit cost 
The unit costs of different surgical treatments were based on the reimbursement systems in 
Norway. With the introduction of activity-based funding in 1997, financing of somatic hospitals 
in Norway evolved from block grant financing to mixed financing consisting DRG 
reimbursement (40%) and block grant financing (60%) (Petersen, 2010). 
Unit cost for pharmaceuticals were derived from the Norwegian Medicines Agency’s price data 
base (NOMA, in Norwegian: Statens legemiddelverk). 
The average cost per day in somatic hospital was based on the Norwegian Directorate of 
Health’s (Helsedirektoratet) 2013 annual report on specialist services in Norway (SAMDATA 
2013). 
3.2 Study design  
Risk factor analysis was a register based retrospective cohort study at the national level in 
Norway including patients undergoing primary hip arthroplasty between September 2012 and 
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December 2014. Regression analysis was employed in this study as the statistical tool for 
assessing relationships between variables. SSI status within 30 days after surgery, defined 
according to the CDC definition, was used as dependent variable in a logistic regression 
analysis along with relevant independent variables explaining potential risk factors. These 
independent variables were subdivided into patient demographics, surgery related 
characteristics and hospital related characteristics. Likelihood ratio (LR) chi-square test 
statistic, p-value and pseudo R-squared in both bivariate logistic model and multivariate logistic 
model were used to examine if the model was statistically significant and how well the model 
fitted. 
In terms of the cost analyses, because the mean and median age of total hip arthroplasty and 
hemiarthroplasty patients were both above 67 years, they could then logically be assumed to 
have retired from work, thus the costs of absence from work and related productivity losses 
were excluded in the cost analysis. Besides, data on the costs incurred in the rehabilitation 
institutions were not available. Therefore, this study mainly takes a hospital perspective. 
According to Drummond (Drummond, Stoddart, Torrance, O'Brien, & Stoddart, 2005), there 
are two elements in costing analysis: measurement of the quantities of resource use and the 
assignment of unit costs or prices. Therefore, the hospital cost of treating SSI following primary 
hip arthroplasty was calculated following this equation: 
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑠𝑡 (𝑇𝐶) =  𝑝𝑎 ∗ 𝑞𝑎 + 𝑝𝑏 ∗ 𝑞𝑏 + ⋯ + 𝑝𝑛 ∗ 𝑞𝑛        (1) 
Where a, b… n are notions for different kinds of resources 
The hospital overhead cost, as well as cost of doctor visits and nursing care were assumed to be 
part of the cost of hospital days. 
In order to quantify the resource used for treating SSI, a clinical “pathway” of SSI treatment 
after primary hip prosthesis was established based on the review of clinical guidelines and 
expert opinion. This pathway intends to describe the usual clinical management of SSI. Expert 
opinion was obtained through a structured questionnaire (see Appendix 2-5) that were sent out 
to four orthopedic surgeons in the NOIS reference group who respectively represent the four 
health regions in Norway. Quantification of each resource used was obtained based on the range 
of quantities of each item given by the expert. Unit costs (Table 4) were derived from various 
sources, mainly from authority document such as the Norwegian Directorate of Health’s 
(Helsedirektoratet) 2013 annual report, Norwegian Medicines Agency, etc. 
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All costs were expressed in terms of 2015 Norwegian Krone (NOK).  
3.3 Data Management 
Deep infection and organ/space infection are defined as two different infections according to 
CDC criteria, in this study, however, these two types of infections were combined since 
physicians have reported difficulty in distinguishing deep infection from organ/space infection 
or vice versa in practice. 
Three categorical variables, namely contamination score, ASA score and Nosocomial Infection 
National Surveillance (NNIS) risk index, were recoded into fewer categories respectively based 
on evidence from previous literature (Namba et al., 2012 October; S. Ridgeway et al., 2005). 
Due to the same reason, two continuous variables: duration of surgery and pre-operation 
hospital stay were recoded into categorical ones.  
Missing data:  
For the data used in the logistic regression, there were 2150 missing data points across a 
multiplicity of variables, composing 8.7% of the total data points. In Stata, the default method 
of dealing with missing data is listwise deletion, also known as complete case analysis, meaning 
that regression model uses just those cases with complete data for all the variables in the model. 
This listwise deletion might be a reasonable approach when the discarded cases form a 
representative and relatively small portion of the entire dataset. However, on the other hand, 
listwise deletion implicitly assumes the discarded cases represent a random subsample, which 
may well not be the case in this study since the missing cases could possibly differ 
systematically from the rest, for example, reoperation data is systematically missing for non-
infection cases. Then consequently, estimates made by this method would be biased. Therefore, 
in order to avoid the possibility of decreasing statistical power, introducing bias and affecting 
the representativeness of the results, case deletion should not be adopted in risk factor analysis. 
Instead, a commonly used method of grouping the missing values as another category for each 
variable was employed to deal with the missing data. 
3.4 Analyses 
Each analysis performed in this study will be described more thoroughly in this part. 
3.4.1 Risk factor analysis  
After categorizing indicator variables into three groups, namely patient-related characteristics, 
surgery-related characteristics and hospital-related characteristics (Table 2), descriptive 
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statistics were computed for all study variables to describe and explore the dataset. The 
frequency distributions of surgical site infection status among the categories of patient-, 
surgery- and hospital-related characteristics were compared using chi-square test (or Fisher’s 
exact test when there existed one or more of the cells had an expected frequency of five or less). 
Continuous variables such as age, post-operative hospital stay and follow-up time were 
investigated using independent samples t-test.   
In order to identify and quantify the factors that determined whether or not a primary hip 
arthroplasty patient developed surgical site infection, a binary logistic regression model was 
constructed. In this model, infection status was modeled as a function of patient, procedure and 
hospital characteristics. Outcome variables describing patients’ infection status had two 
categories, 0 and 1, representing no infection detected in one case and infection detected in the 
other case.  
Let  be the observed binary outcome variable indicating no infection and infection with 
numbers 0 and 1 respectively; 𝑥  was an individual independent variable. The estimated 
probability of infection ( = 1) given 𝑥 could then be noted as π(𝑦|𝑥). It is the probability of 
being infected that was modeled in relation to a series of independent variables. 
The logistic regression model is: 
ln [
π(𝑦|𝑥)
1 − π(𝑦|𝑥)
] = 𝛽0 + 𝛽1 ∗ 𝑥1 + 𝛽2 ∗ 𝑥2 + ⋯ + 𝛽𝑘 ∗ 𝑥𝑘 
Where 𝑥𝑘 was the individual explanatory variable, 𝛽𝑘was the estimated coefficient for 𝑥𝑘 
Independent (explanatory) variables included in the regression model 
Variables deemed to be possible risk factors for SSI from previous literatures were included as 
independent variables. In addition, exploring the effects of hospital region; hospital type and 
hospital size on the probability of developing SSI was possible given having relevant data in 
the NOIS dataset. All the independent variables were grouped into patient characteristics, 
surgery characteristics and hospital characteristics.  
  
y
y
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Patient characteristics 
Patient characteristics were measured using age, gender and ASA physical status. ASA score 
is an assessment by the anesthesiologist of the patient’s preoperative physical condition using 
the American Society of Anesthesiologists’ (ASA) classification of physical status 
(Anesthesiologists, 2014). Patients were assigned one of the following points: 
I  A normally healthy patients 
II  A patient with mild systemic disease 
III A patient with severe systemic disease 
IV A patient with severe systemic disease that is a constant threat to life 
V A moribund patient who is not expected to survive without the operation 
VI A declared brain-dead patient whose organs are being removed for donor purposes 
In this study, ASA status of III, IV and V were merged into one group indicating any score ≥ 
III.  
Surgery related characteristics were as following: 
Wound contamination  
The American College of Surgeons determines four classes of surgical wound types based on 
the wound’s level of contamination: clean, clean-contaminated, contaminated and dirty-
infected. These classes allow health care professionals to better predict the risk of infections 
and wound healing outcomes. Detailed classification criteria for each class has been made into 
a table attached as Appendix 6. In this study, the variable wound contamination was simplified 
with two outcomes: clean versus all the others (clean-contaminated, contaminated and dirty-
infected) due to the fact that primary hip arthroplasty was normally considered a clean wound 
surgery.  
Duration of surgery  
Duration of surgery was measured in minutes from surgery start time to finish time. Instead of 
using it as a continuous variable, it was grouped into four values: less than 60 minutes; 61 to 
90 minutes; 91 to 120 minutes and more than 120 minutes. 
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NNIS risk index  
The index value that ranges from 0 to 3 points is obtained from scoring one point when each of 
the following presents: (1) ASA physical status classification > II, (2) either contaminated or 
dirty/infected wound classification, (3) length of operation > T hours, where T is the 
approximate 75 percentile of the duration of the operation being performed.  
Since NNIS risk index, by its definition, is obviously highly correlated with those three 
variables listed above, the estimation of this variable wound create multicollinearity. Therefore 
NNIS risk index categories were excluded from the multivariate analysis. 
Elective surgery 
This is a binary variable indicating whether the surgery was elective or not. It was coded as 0 
and 1 representing emergency operation and elective operation respectively. Elective surgery 
is a surgery that is medically necessary, but can be delayed for at least 24 hours. Emergency 
operation on the other hand was a non-elective, unscheduled procedure where the standard 
immediate preoperative preparation that normally done within the facility was not allowed. 
Perioperative antibiotic prophylaxis 
It is the indicator of if antimicrobial therapy was used for the prevention of infection. And there 
were three categories: yes, no and unknown. 
Cement 
When the existing joint surface is replaced with artificial joint prostheses in the surgery, the 
orthopedic surgeon must make sure that the prostheses adhere to patient’s natural bone. How 
this adhesion is achieved depends on what kind of prosthesis is used: a cemented joint prosthesis 
uses fast-drying bone cement to help fix it to the bone; a cement-less joint prosthesis allows the 
bone to grow onto it and adhere to it over time. This variable indicates whether a cemented joint 
prosthesis or a cement-less joint prosthesis or a hybrid prosthesis was used in each surgery. 
Pre-operative stay 
This is a continuous variable measuring the days patients spent in hospital before undergoing 
surgery. 
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Post-operative stay 
It describes this time period from the moment when operation was finished to the time patient 
was discharged from hospital. 
Follow-up time 
The time period patients were followed up by hospitals, measured in day. Hospitals were 
required to follow each patient for 30 days after surgery and the NIPH requested a minimum of 
80% post-discharge follow-ups from the hospitals (Løwer et al., 2013). 
Additionally, there were another three independent variables describing hospital characteristics: 
Hospital region 
There are four geographical health care regions in Norway: South-Eastern, Western, 
Middle/Central and Northern (Appendix 1). Private hospital were categorized as “private” 
alongside the four health regions. 
Type of hospital 
Each hospital was categorized as one of the five types: primary, secondary, specialized, tertiary 
and unknown, according to the level of health care it provided. 
Hospital size 
Hospital size was measured using the number of hospital beds, and the three categories were 
large (>700), medium (301 to 700) and small (<300). 
Considering that all independent variables chosen for this study had medical reasons for being 
of interest and the dataset was sufficiently large, therefore, all these independent variables 
except NNIS risk index were included in the multivariate logistic regression regardless of its 
significance in bivariate model. Odds ratio (OR), 95% confidence interval (CI) and p-value are 
provided for all the independent variables. 
Data were analyzed using Stata®13 (Stata Corp., College Station, Texas) and a p-value < 0.05 
was set as the statistical significance threshold. 
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3.4.2 Cost analysis  
Michael F. Drummond and his colleagues identified the main categories of costs of health care 
programs as costs arising from the use of resources within the health sector; the resource use 
by patients and their families; the resource use in other sectors and productivity change 
(Drummond et al., 2005). In practice, the particular range of costs included in a given study is 
usually decided upon the viewpoint for the analysis and availability of data. Possible viewpoints 
of study include those of society, which is the broadest one, the health sector, the government 
in general, the hospital and the patient, etc. Specifying the viewpoint or perspective of the study 
is crucial because some items are costs from one point of view, but not costs from another point 
of view. Take the patient’s transportation fee as an example: it is a cost from patient’s point of 
view, but not a cost from a health sector perspective.  
After the relevant range of costs being identified, each individual item must be measured and 
valued. That is, costing has two basic elements: measurement of the quantities of resource use 
(q) and the assignment of unit costs or prices (p) to each kind of resource (Drummond et al., 
2005). Resource quantities could either be collected on the case report forms or be estimated 
by reviewing hospital records, depending on the context for the economic evaluation. With 
respect to the assignment of unit costs or prices, even though the theoretical true cost of using 
scarce healthcare resource is the value of the resource in its next best alternative use, or referred 
as “opportunity cost”, the pragmatic approach is to use existing market prices unless particular 
reason suggesting otherwise (Drummond et al., 2005). 
Costing can be time and effort consuming, so before proceeding to cost calculation, it is 
important for analysts to decide how accurate the costing need to be. In costing for hospital 
costs, there are four levels of precision, namely micro-costing, case-mix group, disease-specific 
per diem and average per diem (Drummond et al., 2005). When follow micro-costing, each 
resource component is identified and a unit cost assigned. Case-mix group (where diagnosis 
related groups fall into) gives the cost for each category of case and the other two give average 
daily cost. The other two give average daily cost in disease specific category or over all 
categories, making them the least precise.  
Then the calculation of total cost requires the quantities of resource use (q) being multiplied by 
the unit costs (p) of the resources (Equation (1)).  
In the present study, costs arising from the use of resources in hospital were estimated. The 
range of costs included in the analysis were costs of inpatient stay, outpatient clinic visits, 
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imaging examination, laboratory tests, pharmaceuticals and costs associated with readmissions 
due to SSI, if there was any.  
Equation (1) could be rewritten as: 
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑠𝑡 (𝑇𝐶) = 𝑞𝐿𝑂𝑆 ∗ 𝑝𝐿𝑂𝑆 + 𝑞𝑅𝑒𝑎𝑑 ∗ 𝑝𝑅𝑒𝑎𝑑 + 𝑞𝑅𝑒𝑜𝑝 ∗ 𝑝𝑅𝑒𝑜𝑝 + 𝑞𝑂𝑢𝑡 ∗ 𝑝𝑂𝑢𝑡 + 𝑞𝐴𝑏 ∗
𝑝𝐴𝑏 + 𝑞𝑃𝑙𝑎 ∗ 𝑝𝑃𝑙𝑎 + 𝑞𝑋𝑟𝑎𝑦 ∗ 𝑝𝑋𝑟𝑎𝑦 + 𝑞𝐴𝑟𝑡ℎ ∗ 𝑝𝐴𝑟𝑡ℎ + 𝑞𝐵𝑙𝑜𝑜𝑑 ∗ 𝑝𝐵𝑙𝑜𝑜𝑑 + 𝑞𝐵𝑐𝑡 ∗ 𝑝𝐵𝑐𝑡                     
(2) 
Where LOS = length of stay, Read = readmission, Reop = reoperation, Out = outpatient clinic, 
Ab = antibiotics, Pla = plaster, Xray = X-ray examination, Arth = arthrocentesis, Blood = blood 
test, Bct = bacteriological test. 
Data on quantities of resources used was collected through the orthopedic surgeon survey 
(Table 3).    
Table 3 Quantities of health care resources used for treating SSI following primary hip 
arthroplasty in Norway* 
Resources 
No 
infection 
Superficial 
infection Deep or Organ/Space infection 
    
DAIR or One-stage 
revision 
Two-stage 
revision Resection 
Additional LOS 0 0.83 2.18 2.18 2.18 
            
Readmission stay 0 0 14 21 14 
            
Out-patient clinic 
visits 4 4 9 14 7 
            
Wound care           
Plaster 3 3 8 13 13 
Laboratory           
Blood test 0 0 14 20 14 
Bacteriological 
test  0 0 6-9 11-17 6-9 
            
X-ray 
investigation 6 6 6 6 4 
Arthrocentesis 0 0 1 1 1 
            
Reoperation           
Debridement and 
retention  0 0 1 NA NA 
One-stage revision 0 0 1 NA NA 
Two-stage 
revision 0 0 NA 1 NA 
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Resection 0 0 NA NA 1 
            
Antibiotics §           
Cefalotin 2g*4*1  2g*4*1 2g*4*1 2g*4*1 2g*4*1 
Rimactan 0 0 300mg*2*90 0 0 
Vancomicin 0 0 1g*2*7 1g*2*7 1g*2*7 
Ciproxin 0 0 750mg*2*83 0 0 
Ekvacillin 0 0 0 2g*4*7 2g*4*7 
Diclocil 0 0 0 1g*4*76 1g*4*28 
* Based on information from one clinical expert except the data on prolonged length of stay (from the NOIS)           
§ 2g*4*1 means 2g*4 dose per day for 1 day 
 
As showed in Table 4, in lack of opportunity costs, I have used Norwegian DRG price list (unit 
cost NOK 41,462), SAMDATA report and the Norwegian Medicines Agency (Statens 
Legemiddelverk) database to estimate the unit cost of laboratory tests, inpatient stay, surgical 
treatment and pharmaceutical, etc. The cost of health personnel was not listed in the table 
because the average time health personnel spent on a single patient during the inpatient stay 
varied greatly based on individual surgeon or nurse; therefore, it was difficult for experts to 
measure in the survey. And more importantly, it was assumed to have been included in the cost 
of inpatient stay so it would be double-counted if listed separately. 
Given the quantities of resources use and their unit costs, the total hospital cost was then 
calculated following equation (1). 
Table 4 Unit cost of each kind of resource used in hospital for treating surgical site infection 
Type of cost Type of unit 
Cost 
(NOK) 
DRG number 
(Weight*****) Source 
Average cost per day in 
somatic hospital Day 15,008* NA SAMDATA report 2013 
          
Out-patient clinic Visit 995 DRG908A (0.024) DRG price list 2015 
          
Wound care         
Plaster 
Application of 
plaster 995 DRG908A (0.024) DRG price list 2015 
Laboratory tests         
Blood test Test  10**  707a Lovdata 
Bacteriological test of 
wounds Test  50***  704a Lovdata 
          
X-ray investigation X-ray examination  130  RG2 Lovdata 
Arthrocentesis Number 1990 DRG808U (0.048) DRG price list 2015 
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Reoperation         
Debridement and 
retention  Operation 92,543 DRG210N (2.232) DRG price list 2015 
One-stage revision Operation 92,543 DRG210N (2.232) DRG price list 2015 
Two-stage 
revision/Replacement of 
hip prosthesis Operation 225,056 DRG209C (5.428) DRG price list 2015 
Excision, in-patient Operation 33,418 DRG230 (0.806) DRG price list 2015 
Excision, out-patient Operation 13,309 DRG230O (0.321) DRG price list 2015 
          
Antibiotics ****         
Cefalotin Pack (2g*10) 374 NA Norwegian Medicines Agency 
Rimactan Pack (300mg*100) 437 NA Norwegian Medicines Agency 
Vancomycin Pack (1g*1) 141 NA Norwegian Medicines Agency 
Ciproxin Pack (750mg*100) 764 NA Norwegian Medicines Agency 
Ekvacillin Pack (2g*10) 197 NA Norwegian Medicines Agency 
Diclocil Pack (1g*5) 86 NA Norwegian Medicines Agency 
* NOK 14,638 in 2013, adjusted for inflation 
** One test per visit 
*** Five tests per visit 
**** All prices are without VAT 
   
 
3.5 Ethical consideration 
Patient data were de-identified before the submission to the NIPH, so there was no identifiable 
individual level data contained in this thesis. Collection and use of NOIS data is governed by 
an own act NOIS-registerofrskriften. The project was approved by the PVO at the Norwegian 
Institute of Public Health (NIPH). 
4   Results  
4.1 Brief overview 
Between September 2012 and December 2014, 53 hospitals contributed data on a total of 17,762 
total hip arthroplasty operations while 46 hospitals reported data on 7334 hemiarthroplasty 
procedures. From the day of surgery to 30 days afterwards, 390 (2.2%) total hip arthroplasty 
patients and 264 (3.6%) of hemiarthroplasty patients were diagnosed with SSIs. Of all the 390 
infection cases after total hip arthroplasty, 206 (53%) were superficial and 184 (47%) were deep 
or organ/space infections, while for hemiarthroplasty infections, the number of superficial 
infection was 113 (43%) and 151 (57%) were deep or organ/space infections.   
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4.2 Descriptive statistics on central variables 
4.2.1 Total hip arthroplasty (THA) 
4.2.1.1 Patient characteristics 
The majority of arthroplasty patients (n=11,593) were females, making up to 65% of the study 
population while 6169 (35%) were males. Compared with male patients, female patients had a 
lower proportion of infection (2.0% vs. 2.6%, p < 0.01). The overall mean age for THA patients 
was 68 years (SD 11.1). Patients with SSI were 1.4 years older than those without (p = 0.01). 
With respect to ASA score, patients with a score higher than or equal to III had a higher risk of 
acquiring infection (3.9% vs. 1.8%, p < 0.01) comparing with those had an ASA score of I and 
II. 
Table 5 Characteristics of total hip arthroplasty (THA) patients in Norway between September 
2012 and December 2014, by surgical site infection (SSI) status. 
Variable Not infected (n=17372) Infected (n=390) Total (N=17762) p-value 
Age (yrs)         
  Mean (SD) 68.0 (11.1) 69.4 (11.2) 68.0 (11.1) 0.01 
  Median 69 70 69  
  Min, Max 11, 102 23, 96 11, 102  
Sex     
  Male 6009 (97.4 %) 160 (2.6 %) 6169 (100 %) < 0.01 
  Female  11363 (98.0 %) 230 (2.0 %) 11593 (100 %)  
ASA category      
  I and II 13850 (98.2 %) 258 (1.8 %) 14108 (100 %) < 0.01 
  ≥ III 3103 (96.1 %) 125 (3.9 %) 3228 (100 %)  
  Missing 419 (98.4 %) 7 (1.6 %) 426 (100 %)  
 
4.2.1.2 Surgery characteristics 
A greater proportion of infected patients was found among patients with a higher-than-1 NNIS 
risk index than among those with an index of 0 or 1 (4.6% vs. 2.1%, p < 0.01). 2.8% of the 
surgeries where prosthesis was fixed without cement were infected within 30 days after surgery 
while for surgeries using cement or hybrid fixation the infection proportion was 2% (Table 6). 
On average, THA patients stayed in hospital for 4.1 days (range 0-340, SD 4.6) after surgery. 
Infected patients stayed longer (5.6 days, range 0-107, SD 8.5) at hospital after surgery than 
those without infection (4.1 days, range 0-340, SD 4.5) (p < 0.01). 
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Table 6 Surgery characteristics of total hip arthroplasty (THA) in Norway between September 
2012 and December 2014, by surgical site infection (SSI) status 
Variable 
Not infected 
(n=17372) 
Infected (n=390) Total (N=17762) p-value 
Wound contamination          
  Clean 16862 (97.8 %) 373 (2.2 %) 17235 (100 %) 0.18 
  Other 112 (95.7 %) 5 (4.3 %) 117 (100 %)  
  Missing 398 (97.1 %) 12 (2.9 %) 410 (100 %)  
Duration of surgery (min)      
  < 60 2729 (98.3 %) 48 (1.7 %) 2777 (100 %) 0.15 
  61 to 90 7543 (97.7 %) 175 (2.3 %) 7718 (100 %)  
  91 to 120 4683 (97.9 %) 99 (2.1 %) 4782 (100 %)  
  >120 2221 (97.2 %) 63 (2.8 %) 2284 (100 %)  
  Missing 196 (97.5 %) 5 (2.5 %) 201 (100 %)  
NNIS risk index      
  0 or 1 16224 (97.9%) 348 (2.1%) 16572 (100%) < 0.01 
  2 or 3 515 (95.4%) 25 (4.6%) 540 (100%)  
  Missing 633 (97.4%) 17 (2.6%) 650 (100%)  
Elective surgery     
  Yes 16175 (97.8%) 370 (2.2%) 16545 (100%) 0.22 
  No 1161 (98.3%) 20 (1.7%) 1181 (100%)  
Peri-operative 
prophylaxis§     
  Yes 16041 (97.9%) 384 (2.1%) 16389 (100%) 0.07 
  No 482 (97.0%) 15 (3.0%) 497 (100%)  
  Unknown 838 (96.9%) 27 (3.1%) 865 (100%)  
Cement      
  Yes 5342 (98.0%) 111 (2.0%) 5453 (100%) < 0.01 
  No 4534 (97.2%) 129 (2.8%) 4663 (100%)  
  Hybrid 7496 (98.0%) 150 (2.0%) 7646 (100%)  
Pre-operation stay (day)     
  Mean (SD) 0.85 (1.2) 0.83 (1.2) 0.85 (1.2) 0.13 
  Median 1.0 1.0 1.0  
  Min, Max 0, 51 0, 13 0, 51  
Post-operation stay (day)     
  Mean (SD) 4.10 (4.5) 5.57 (8.5) 4.14 (4.6) < 0.01 
  Median 3.0 4.0 3.0  
  Min, Max 0, 340 0, 107 0, 340  
 
4.2.1.3 Hospital characteristics 
Three variables, hospital region, type of hospital and number of hospital beds, were used to 
describe hospitals. 
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As illustrated in Table 7, despite that only 7% of the procedures were done in hospitals that 
belonged to the Northern Norway Regional Health Authority (Helse Nord RHF), they had the 
highest proportion of infection (3.7% (45 out of 1207)). Followed by those performed by 
Middle/Central Norway Regional Health Authority (Helse Midt RHF) (3.1% (82 of 2650)), 
hospitals in South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF) (2.4% (172 
of 7061)), then those in the Western Norway Regional Health Authority (Helse Vest RHF) 
(1.8% (50 of 2833)), and finally private hospitals (1.0% (41 of 4011)).  
Infection proportions among the four hospital types were also significantly different. In 
specialty hospitals only 0.5% (11 of 2163) of THAs were infected whereas in the other types 
of hospitals (primary, secondary and tertiary) about 2.5% of the surgeries were reported as 
infected. 
Table 7 Hospital characteristics of total hip arthroplasty (THA) in Norway between September 
2012 and December 2014, by surgical site infection (SSI) status 
Variable Not infected (n=17372) Infected (n=390) Total (N=17762) p-value 
Hospital region         
  Middle 2568 (96.9 %) 82 (3.1%) 2650 (100%) < 0.01 
  Northern 1162 (96.3 %) 45 (3.7%) 1207 (100%)  
  South-Eastern 6889 (97.6 %) 172 (2.4%) 7061 (100%)  
  Western 2783 (98.2 %) 50 (1.8%) 2833 (100%)  
  Private 3970 (99.0 %) 41 (1.0%) 4011 (100%)  
Type of hospital     
  Primary 7574 (97.5%) 192 (2.5%) 7766 (100%) < 0.01 
  Secondary 4067 (97.6%) 102 (2.5%) 4169 (100%)  
  Specialty 2152 (99.5%) 11 (0.5%) 2163 (100%)  
  Tertiary 2834 (97.5%) 72 (2.5%) 2906 (100%)  
  Unknown 745 (98.3%) 13 (1.7%) 758 (100%)  
Number of hospital beds     
  0 to 300 10994 (98.0%) 230 (2.1%) 11224 (100%) 0.12 
  301 to 700 4455 (97.4%) 118 (2.6%) 4573 (100%)  
  > 700 1923 (97.9%) 42 (2.1%) 1965 (100%)  
 
4.2.2 Hemiarthroplasty (HA) 
4.2.2.1 Patient characteristics 
The mean age of patients who underwent hemiarthroplasty during the study period was 83 years 
(SD 8.4); making them almost 15 years older than total hip arthroplasty patients. The proportion 
of females was 71% (5199 out of 7334).  Male patients had a higher risk of infection than female 
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ones (4.9% vs 3.1%, p < 0.01). As for ASA scores, patients with a score  ≥ III doubled the 
infection proportion when compared with those with score I and II (4.4% vs. 2.2%, p < 0.01).  
Table 8 Characteristics of hemiarthroplasty (HA) patients in Norway between September 2012 
and December 2014, by surgical site infection (SSI) status 
Variable Not infected (n=7070) Infected (n=264) Total (N=7334) p-value 
Age (yrs)         
  Mean (SD) 82.7 (8.4) 82.2 (8.4) 82.7 (8.4) 0.40 
  Median 84 83 84  
  Min,Max 16,102 44,98 16,102  
Sex     
  Male 2031 (95.1%) 104 (4.9%) 2135 (100%) < 0.01 
  Female  5039 (96.9%) 160 (3.1%) 5199 (100%)  
ASA category     
  I and II 2596 (97.8%) 59 (2.2%) 2655 (100%) < 0.01 
  ≥ III 4350 (95.6%) 201 (4.4%) 4551 (100%)  
  Missing 124 (96.9%) 4 (3.1%) 128 (100%)  
 
4.2.2.2 Surgery characteristics 
In Norway, more than 80% of hemiarthroplasties performed during study period were 
emergency procedures that lasted less than 2 hours. Generally, patients spent 1.1 days in 
hospital before the surgery and another 5.2 days afterwards. Perioperative antibiotic 
prophylaxis was administered in 92% of the operations and 71% of the procedures used 
cemented component for prosthesis fixation. 
However, no statistically significant difference in infection proportions according to the surgery 
characteristics listed in Table 9 was found. 
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Table 9 Surgery characteristics of hemiarthroplasty in Norway between September 2012 and 
December 2014, by surgical site infection (SSI) status 
Variable Not infected (n=7070) Infected (n=264) Total (N=7334) p-value 
Wound contamination         
  Clean 6898 (96.4%) 259 (3.6%) 7157 (100%) 0.60 
  Other 67 (95.7%) 3 (4.3%) 70 (100%)  
  Missing 105 (98.1%) 2 (1.9%) 107 (100%)  
Duration of surgery (min)     
  < 60 1764 (96.6%) 62 (3.4%) 1826 (100%) 0.94 
  61 to 90 3247 (96.5%) 119 (3.5%) 3366 (100%)  
  91 to 120 1476 (96.1%) 60 (3.9%) 1536 (100%)  
  > 120 537 (96.2%) 21 (3.8%) 558 (100%)  
  Missing 46 (95.8%) 2 (4.2%) 48 (100%)  
NNIS risk index     
  0 or 1 6542 (96.5%) 241 (3.6%) 6783 (100%) 0.10 
  2 or 3 334 (94.6%) 19 (5.4%) 353 (100%)  
  Missing 194 (98.0%) 4 (2.0%) 198 (100%)  
Elective surgery*     
  Yes 868 (96.4%) 32 (3.6%) 900 (100%) 0.94 
  No 6200 (96.4%) 232 (3.6%) 6432 (100%)  
Peri-operative prophylaxis§     
  Yes 6479 (96.4%) 241 (3.6%) 6720 (100%) 0.57 
  No 103 (98.1%) 2 (1.9%) 105 (100%)  
  Unknown 477 (96.0%) 20 (4.0%) 497 (100%)  
Cement      
  Yes 5022 (96.5%) 182 (3.5%) 5204 (100%) 0.46 
  No 2048 (96.2%) 82 (3.9%) 2130 (100%)  
Pre-operation stay (day)     
  Mean (SD) 1.10 (1.7) 1.09 (1.4) 1.1 (1.7) 0.38 
  Median 1.0 1 1  
  Min,Max 0,60 0,12 0,60  
Post-operation stay (day)     
  Mean (SD) 5.17 (5.3) 6.66 (8.4) 5.22 (5.4) 0.41 
  Median 4.0 4.0 4.0  
  Min, Max 0, 158 0, 53 0, 158  
* n = 7332 
§ n = 7322 
 
4.2.2.3 Hospital characteristics 
Patients in Northern Norway (Helse Nord RHF) hospitals had the highest infection risk while 
patients operated in private ones had the lowest. When sorted by type, most of the hospitals had 
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an infection percentage between 3%-4%, whereas specialty hospitals had an infection 
proportion of 0% (0 out of 3). The difference, however, was not significant due to limited patient 
number in specialty hospital. The number of hospital beds seemed to be positively associated 
with infection, but the association was not statistically significant. 
Table 10 Hospital characteristics of hemiarthroplasty in Norway between September 2012 and 
December 2014, by surgical site infection (SSI) status 
Variable Not infected (n=7070) Infected (n=264) Total (N=7334) p-value 
Hospital region         
  Middle 1018 (95.7%) 46 (4.3%) 1064 (100%) 0.07 
  North 564 (95.0%) 30 (5.1%) 594 (100%)  
  South-east 3775 (96.5%) 139 (3.6%) 3914 (100%)  
  West 1098 (97.1%) 33 (2.9%) 1131 (100%)  
  Private 615 (97.5%) 16 (2.5%) 631 (100%)  
Type of hospital     
  Primary 3169 (96.8%) 105 (3.2%) 3274 (100%) 0.51 
  Secondary 2090 (96.3%) 81 (3.7%) 2171 (100%)  
  Specialty 3 (100%) 0 (0) 3 (100%)  
  Tertiary 1723 (95.9%) 74 (4.1%) 1797 (100%)  
  Unknown 85 (95.5%) 4 (4.5%) 89 (100%)  
Number of hospital beds     
  0 to 300 3388 (96.7%) 114 (3.3%) 3502 (100%) 0.18 
  301 to 700 2646 (96.3%) 102 (3.7%) 2748 (100%)  
  > 700 1036 (95.6%) 48 (4.4%) 1084 (100%) 
  
4.3 Results from logistic regression  
The bivariate and multivariate associations of each of the possible risk factors investigated with 
infection status are shown in Table 11 (THA) and Table 12 (Hemiarthroplasty).  
4.3.1 Risk factors for SSI after THA 
In bivariate regression, the variables that were associated with higher risk of developing surgical 
site infections after THA were age, male gender, ASA score ≥ III, surgery lasting longer than 
120 minutes, NNIS risk index > 1, cement-less fixation, post-operative hospital stay and 
medium size hospital (hospitals with 301 to 700 beds) (Table 11). Those associated with lower 
infection risk were private hospital, public hospitals that belonged to the Western Norway 
Regional Health Authority (Helse Vest RHF) and specialty hospital. Variables such as wound 
contamination, elective surgery, perioperative antibiotic prophylaxis, pre-operation stay, 
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though not significantly associated with infection in the bivariate analysis, were also included 
in the multivariate model due to their clinical importance.              
The multivariate model showed the independent risk factors for SSI while adjusting for other 
risk factors. According to the multivariate model, the odds of developing surgical site infection 
for males were 1.27 (95% CI 1.03 to 1.56; p = 0.03) times greater than for females. The risks 
of surgical site infection varied according to the duration of surgery, with the greatest risk for 
procedures that lasted more than 120 minutes (OR 1.78, compared with the ones < 60 minutes).  
Although only 26% of the THAs used cement-less component for prosthesis fixation, their 
infection risk was 84% higher than that for cemented procedures. In addition, patients 
undergoing elective total hip arthroplasty procedures were 1.87 times (95% CI 1.17 to 3.00, p 
< 0.01) more likely to have SSI compared with those undergoing non-elective ones.  
The odds of developing surgical site infection when perioperative antibiotic prophylaxis was 
administered were 0.51 (95% CI: 0.28 to 0.93) times as the odds when it was not used. For the 
Western Norway RHA (Helse Vest RHF) hospitals, the risk of surgical site infection were 40% 
(OR 0.6, p = 0.02) lower than that for hospitals belonged to the Middle/Central Norway RHA 
(Helse Midt RHF); and for private hospitals the infection risk was only 0.36 times as that for 
middle/central RHA hospitals (OR 0.36, p < 0.01). Furthermore, the odds of infection in 
specialty hospital were 66% (OR 0.34, p < 0.01) less than in primary hospitals.   
After adjusting for other variables, elective surgery and no perioperative antibiotic prophylaxis 
became risk factors for SSIs while the number of hospital beds between 301 and 700 was no 
longer one. 
Table 11 Risk factors for developing SSI after THA, Norway, between September 2012 and 
December 2014 
  
Bivariate Multivariate 
Odds ratio 95 % CI§ p-value Odds ratio 95 % CI§ p-value 
Patient characteristics       
Age (1-year increment) 1.01 1.00 to 1.02 0.01 1.01 1.00 to 1.02 0.02 
Gender       
  Female  1.00 Baseline  1.00 Baseline  
  Male 1.32 1.07 to 1.61 0.01 1.27 1.03 to 1.56 0.03 
ASA score        
  1 and 2 1.00 Baseline  1.00 Baseline  
  ≥3 2.16 1.74 to 2.69 < 0.01 1.87 1.48 to 2.36 < 0.01 
  Missing 0.90 0.42 to 1.91 0.78 0.45 0.11 to 1.86 0.27 
Procedure characteristics       
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Wound contamination       
  Clean 1.00 Baseline  1.00 Baseline  
  Other 2.02 0.82 to 4.97 0.13 2.07 0.83 to 5.14 0.12 
  Missing 1.36 0.76 to 2.44 0.30 1.65 0.80 to 3.41 0.18 
Duration of surgery 
(minutes)       
  < 60 1.00 Baseline  1.00 Baseline  
  61 to 90 1.32 0.96 to 1.82 0.09 1.35 0.96 to 1.90 0.09 
  91 to 120 1.20 0.85 to 1.70 0.30 1.31 0.89 to 1.92 0.17 
  > 120 1.61 1.10 to 2.36 0.01 1.78 1.16 to 2.73 < 0.01 
  Missing 1.45 0.57 to 3.68 0.43 1.92 0.35 to 10.65 0.45 
Elective surgery       
  No 1.00 Baseline  1.00 Baseline  
  Yes 1.33 0.84 to 2.09 0.22 1.87 1.17 to 3.00 < 0.01 
Perioperative prophylaxis       
  No 1.00 Baseline  1.00 Baseline  
  Yes 0.70 0.41 to 1.18 0.18 0.51 0.28 to 0.93 0.03 
  Unknown 1.04 0.55 to 1.97 0.92 0.92 0.47 to 1.81 0.81 
Cement       
  Yes 1.00 Baseline  1.00 Baseline  
  No 1.37 1.06 to 1.77 0.02 1.84 1.35 to 2.51 < 0.01 
  Hybrid 0.96 0.75 to 1.23 0.77 1.24 0.93 to 1.65 0.15 
Pre-operation stay (days)       
  ≤1 1.00 Baseline  1.00 Baseline  
  >1 1.07 0.78 to 1.46 0.68 1.32 0.95 to 1.84 0.10 
Post-operation stay (days) 1.02 1.01 to 1.03 < 0.01 1.02 1.01 to 1.03 < 0.01 
Hospital characteristics       
Hospital region       
  Middle 1.00 Baseline  1.00 Baseline  
  North 1.21 0.84 to 1.76 0.31 0.99 0.65 to 1.52 0.98 
  South-east 0.78 0.60 to 1.02 0.07 0.77 0.56 to 1.06 0.11 
  West 0.56 0.39 to 0.80 < 0.01 0.60 0.39 to 0.92 0.02 
  Privat 0.32 0.22 to 0.47 < 0.01 0.36 0.23 to 0.54 < 0.01 
Type of hospital       
  Primary 1.00 Baseline  1.00 Baseline  
  Secondary 0.99 0.78 to 1.26 0.93 0.99 0.55 to 1.75 0.96 
  Specialty 0.20 0.11 to 0.37 < 0.01 0.34 0.18 to 0.66 < 0.01 
  Tertiary 1.00 0.76 to 1.32 0.99 1.42 0.68 to 2.95 0.35 
  Unknown 0.69 0.39 to 1.21 0.20 0.63 0.34 to 1.17 0.14 
Number of hospital beds       
  0 to 300 1.00 Baseline  1.00 Baseline  
  301 to 700 1.27 1.01 to 1.58 0.04 0.76 0.42 to 1.37 0.36 
  > 700 1.04 0.75 to 1.46 0.80 0.47 0.21 to 1.07 0.07 
NNIS risk index       
  0 or 1 1.00 Baseline  -## - - 
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  2 or 3 2.26 1.49 to 3.43 < 0.01 - - - 
  Missing  1.25 0.76 to 2.05 0.37 - - - 
§ Confidence Interval             ## Variable excluded because of multicollinearity 
4.3.2 Risk factors for SSI after HA 
For hemiarthroplasty, male sex, ASA score ≥  III and longer post-operation stay were 
significant risk factors for SSIs, whereas in multivariate analysis, cement-less surgery was also 
identified as an additional risk factor (Table 12). The infection risks were significantly greater 
for male patients as well as for those with an ASA score ≥ III, when compared with their 
counterparts (OR 1.45 for male, OR 1.91 for ASA score ≥ III, p < 0.01). In cement-less HAs 
the infection risk was 45% higher (OR 1.45, p = 0.02) than in those used cement. The risk of 
surgical site infection increased significantly yet slightly (OR 1.02, p < 0.01) with length of 
post-operative hospital stay. There were no significant associations between the risk of infection 
after hemiarthroplasty procedures and duration of surgery, perioperative antibiotic prophylaxis, 
NNIS risk index as well as any of the hospital characteristics.  
Table 12 Risk factors for SSI after hemiarthroplasty, Norway, between September 2012 and 
December 2014 
  
Bivariate Multivariate 
Odds ratio 95% CI p-value Odds ratio 95% CI p-value 
Patient characteristics             
Age (1-year increment) 0.99 0.98 to 1.01 0.40 0.99 0.98 to 1.01 0.32 
Gender       
  Female  1.00 Baseline  1.00 Baseline  
  Male 1.61 1.25 to 2.08 < 0.01 1.45 1.12 to 1.87 < 0.01 
ASA score        
  I and II 1.00 Baseline  1.00 Baseline  
  ≥ III 2.03 1.51 to 2.73 < 0.01 1.91 1.41 to 2.59 < 0.01 
  Missing 1.42 0.51 to 3.97 0.51 1.20 0.30 to 4.86 0.79 
Procedure characteristics       
Wound contamination       
  Clean 1.00 Baseline  1.00 Baseline  
  Other 1.19 0.37 to 3.82 0.77 0.98 0.30 to 3.18 0.97 
  Missing 0.51 0.12 to 2.07 0.34 0.52 0.11 to 2.53 0.42 
Duration of surgery 
(minutes)       
  < 60 1.00 Baseline  1.00 Baseline  
  61 to 90 1.04 0.76 to 1.43 0.79 1.07 0.75 to 1.46 0.69 
  91 to 120 1.16 0.81 to 1.66 0.43 1.18 0.78 to 1.72 0.42 
  > 120 1.11 0.67 to 1.84 0.68 1.18 0.67 to 1.95 0.54 
  Missing 1.24 0.29 to 5.21 0.77 2.94 0.33 to 15.20 0.29 
Elective surgery       
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  No 1.00 Baseline  1.00 Baseline  
  Yes 0.99 0.68 to 1.44 0.94 0.96 0.63 to 1.46 0.85 
Perioperative prophylaxis       
  No 1.00 Baseline  1.00 Baseline  
  Yes 1.92 0.47 to 7.81 0.37 1.87 0.45 to 7.80 0.39 
  Unknown 2.16 0.50 to 9.38 0.30 1.77 0.39 to 7.99 0.46 
Cement       
  Yes 1.00 Baseline  1.00 Baseline  
  No 1.10 0.85 to 1.44 0.46 1.45 1.05 to 1.99 0.02 
Pre-operation stay (days)       
  ≤1 1.00 Baseline  1.00 Baseline  
  >1 1.00 0.73 to 1.37 0.99 0.89 0.65 to 1.23 0.49 
Post-operation stay (days) 1.03 1.01 to 1.04 < 0.01 1.02 1.01 to 1.04 < 0.01 
Hospital characteristics       
Hospital region       
  Middle 1.00 Baseline  1.00 Baseline  
  North 1.18 0.73 to 1.89 0.50 1.39 0.81 to 2.39 0.23 
  South-east 0.81 0.58 to 1.15 0.24 0.99 0.65 to 1.49 0.95 
  West 0.67 0.42 to 1.05 0.08 0.62 0.37 to 1.03 0.07 
  Privat 0.58 0.32 to 1.03 0.06 0.66 0.34 to 1.26 0.21 
Type of hospital       
  Primary 1.00 Baseline  1.00 Baseline  
  Secondary 1.17 0.87 to 1.57 0.30 1.04 0.41 to 2.65 0.94 
  Specialty 1.00 - - 1.00 - - 
  Tertiary 1.30 0.96 to 1.76 0.09 0.86 0.30 to 2.50 0.79 
  Unknown 1.42 0.51 to 3.94 0.50 1.55 0.53 to 4.58 0.42 
Number of hospital beds       
  0 to 300 1.00 Baseline  1.00 Baseline  
  301 to 700 1.15 0.87 to 1.50 0.33 1.10 0.43 to 2.82 0.85 
  > 700 1.38 0.98 to 1.94 0.07 1.99 0.62 to 6.41 0.25 
NNIS risk index       
  0 or 1 1.00 Baseline  - - - 
  2 or 3 1.54 0.96 to 2.50 0.08 - - - 
  Missing  0.56 0.21 to 1.52 0.26 - - - 
 
4.4 Results of cost analysis 
The costs incurred in hospital after initial hip arthroplasty sorted by infection status is shown in 
Table 13. Patients without infection had a post-operative cost of NOK 7,895 comprising the 
cost of outpatient clinic visit, application of plaster, x-ray examination and antibiotics. 
Compared with non-infected patients, patients with superficial infections spent 2.8 days more 
in hospital after surgery, leading to a higher post-operative cost of NOK 20,352. Costs of the 
most severe infections varied from NOK 303,775 to NOK 611,380 according to the 
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management strategy applied. After incorporating management strategy frequencies, the overall 
average post-operative cost for patients with deep or organ/space infection was NOK 415,382, 
mainly due to a substantial increase in resource use e.g. readmission and reoperation.  
Table 13 Postoperative hospital cost by infection status after primary hip arthroplasty in 
Norway, between September 2012 and December 2014, measured in 2015 Norwegian krone 
  No infection 
Superficial 
infection Deep or Organ/Space infection 
Cost component     
DAIR* or One-
stage revision 
Two-stage 
revision Resection 
Additional LOS 0 12,457 32,717 32,717 32,717 
Readmission 0 0 210,112 315,168 210,112 
Reoperation 0 0 92,543 225,056 33,418 
Outpatient clinic 3,980 3,980 8,955 13,930 6,965 
Antibiotics 150 150 4,178 7,904 4,602 
Plaster 2,985 2,985 7,960 12,935 12,935 
X-ray 780 780 780 780 520 
Arthrocentesis 0 0 1,990 1,990 1,990 
Blood test 0 0 140 200 140 
Bacteriological test 0 0 375 700 375 
Total 7,895 20,352 
359,751 611,380 303,775 
415,382 
* DAIR: Debridement and implant retention  
With these costs being given, the attributable cost due to surgical site infection could then be 
calculated (Table 14). The mean hospital cost for treating a superficial infection was NOK 
12,457, arising from additional length of stay. Similar to the post-operative costs, the 
attributable SSI costs for deep or organ/space infections varied with revision procedures. That 
is, infections treated with DAIR or one-stage exchange had an attributable hospital cost of NOK 
351,856 while those treated with two-stage revisions caused a much higher cost of NOK 
603,485 and the remaining infections treated with resection prosthesis had a lower hospital cost 
of NOK 295,880. After accounting for the proportions of each revision procedure in Norway,  
the overall cost of a deep or organ/space infection for hospital was NOK 407,487.  
Table 14 Costs attributable to SSI by infection status after primary hip arthroplasty in Norway 
between September 2012 and December 2014, measured in 2015 Norwegian krone 
  No infection 
Superficial 
infection Deep or Organ/Space infection 
    
DAIR or One-stage 
revision 
Two-stage 
revision Resection 
Attributable 
cost due to SSI 
0 12,457 
351,856 603,486 295,880 
407,487 
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Despite of the big cost difference between superficial infection (NOK 12,457) and deep or 
organ/space infection (NOK 407,487), their proportions in the infection group were similar 
(superficial infection: 53%; deep or organ/space infection: 47%). Therefore, when emerging 
the two infection groups into a new one that indicated the existence of SSI, the overall cost was 
balanced to NOK 198,121 (Table 15). 
Table 15 Post-operative hospital cost and attributable cost due to SSI sorted by No SSI/SSI after 
primary hip arthroplasty in Norway between September 2012 and December 2014, measured in 
Norwegian Krone 
 No SSI SSI 
Hospital cost after initial surgery 7,895 206,016 
Attributable cost due to SSI 0 198,121 
 
A cost breakdown was shown in Figure 7 to identify the most important cost drivers for SSI. 
More than half (56%) of the hospital costs for treating a SSI was incurred by subsequent 
inpatient stay (readmission to hospital) and 28% came from surgical revision procedures 
(reoperation). Together these two components constituted more than 80% of the SSI cost for 
hospital. The third important cost component was prolonged hospital stay (11%) after the initial 
hip arthroplasty. Other cost items, such as plaster (2%), antibiotics (1%), outpatient clinic (1%), 
were minor ones that could hardly change the total cost on a great scale. 
Figure 7 SSI cost after primary hip arthroplasty in Norway between September 2012 and December 2014 
according to cost component 
Additional 
LOS
11%
Readmissio
n
56%
Reoperation
28%
Outpatient 
clinic
1%
Antibiotics
1%
Plaster
2%
Arthrocente
sis
1%
SSI cost (NOK 198,121) breakdown
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5   Discussion  
5.1 Main findings and implications 
5.1.1 Risk factor analysis 
The overall incidence rate of SSIs following total hip arthroplasty (THA) in a cohort of 17,762 
cases monitored within NOIS was 2.2%. This is similar to that reported from the Surgical Site 
Infection Surveillance Service (SSISS) in England with 16,291 cases (S. Ridgeway et al., 2005) 
but lower than the 1-year incidence (3.0%) observed in NOIS among 5,540 cases from 2005-
2009 (Dale et al., 2011). This could be related to the relatively short follow-up period in NOIS 
after THA that failed to capture the infections diagnosed later than 30 days after surgery. 
Alternatively, it could be an effect of having a surveillance system as it has been shown by 
others (Wilson et al., 2006) that having surveillance lead to lower SSI risk. 
This study evaluated the association of patient characteristics, as well as procedure and hospital 
characteristics with SSIs after THA and HA. Male sex, cement-less fixation and post-operative 
hospital stay were risk factors that common to both SSIs after THA and those after HA. 
Patient-related risk factors for SSI after THA included age, sex and ASA score. Although sex 
is among one of the most frequently detected risk factors for SSI after THA, its influence 
appears to be contradictory in the literature. In our study, male sex had an increased risk of 
infection compared with its female counterparts. The same finding was reported in another 
Norwegian study (Dale et al., 2011) from 2011, although the result was not statistically 
significant. Similarly, investigators in the United States using the National Inpatient Sample 
(NIS) data found that the risk of infection for men was 33% higher than that for women (OR = 
1.33) (Poultsides et al., 2013). In contrast, another US study using joint replacement registry 
data claimed men to have a hazard ratio of 0.70 (Namba et al., 2012 October) and a lower risk 
of infection in male patients was also been found by Dutch researchers (Muilwijk, Walenkamp, 
Voss, Wille, & van den Hof, 2006). The difference of gender effect on SSI might be associated 
with the different underlying physical conditions of both sexes in the country where the study 
was carried out. In Norway, the diabetes mellitus prevalence for men was higher than that for 
women (9.0% vs. 5.1%) (Jenum et al., 2003). And diabetes have been documented as risk factor 
for SSI in a number of studies (Triantafyllopoulos, Stundner, Memtsoudis, & Poultsides, 2015). 
Therefore, a higher risk of SSI for male patients may resulted from the higher risk of diabetes 
for Norwegian men. That is, instead of by itself, the gender effect on SSI risk was due to 
confounder (diabetes) that was not included in the model. In addition, some researchers 
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suggested in their study (Willis-Owen, Konyves, & Martin, 2010) that this could be accounted 
for by gender differences in skin microbial colonization. 
ASA score is an approximate reflection of patient’s general physical status  where a higher score 
indicates a worse physical status. Compared to patients with ASA score of I and II, we observed 
a risk of 1.87 (95% CI 1.48 to 2.36, p < 0.01) for patients with an ASA score ≥ III. This positive 
correlation of ASA score and infection risk after THA is in accordance with previously 
published findings (Dale et al., 2011; Namba et al., 2012 October; S. Ridgeway et al., 2005).  
Another predictor of the risk of SSI was the prolonged duration of surgery. Compared to 
surgeries that lasted less than 60 minutes, the infection risk increased significantly in procedures 
that lasted for 120 minutes or more. As S. Ridgeway and colleagues (S. Ridgeway et al., 2005) 
suggested in their study, the prolonged duration of surgery perhaps served as a marker for “more 
complex surgery, in which existed a combination of prolonged surgical exposure and tissue 
damage during the procedure” and diminished efficacy of antibiotic prophylaxis, which could 
make these surgeries more susceptible to infection. 
Other surgical characteristics associated with higher risk of infection were elective surgery, 
cement-less prosthesis and post-operation stay. Besides, the use of perioperative antibiotic 
prophylaxis was associated with lower risk of infection.  
Although 93% (16545 of 17762) of THAs were elective surgery, compared with emergency 
surgery, it had a higher risk of infection. To my knowledge, no similar finding was reported in 
previous studies. This might be a result of some confounder that was not included in the 
regression model, such as bearing surface, bilateral procedures, etc. Further study needs to be 
done to find out the real reason. According to the Norwegian Arthroplasty Register (T. N. A. 
Register, 2010), nearly all cemented total hip arthroplasties performed in Norway were inserted 
with cement containing antibiotics. Protected both systemically by perioperative antibiotic 
prophylaxis and locally by the antibiotic eluted from cement, cemented hip prosthesis was 
consequently less likely to be infected compared to cement-less ones.  
Perioperative antibiotic prophylaxis is a commonly reported indicator of lower infection risk in 
both the current and previous studies (Triantafyllopoulos et al., 2015) and it is also a standard 
practice for THA. However, despite improved antibiotic prophylaxis, in recent years, an 
increasing incidence of infection after THA was reported in both Norway and other Nordic 
countries (Dale et al., 2012; Dale et al., 2009). Researchers believed that this was an actual 
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increase since no change in risk factors could account for it. And the real reasons for this 
increase were not evident.  
Unlike previous investigators identifying pre-operation stay as a risk factor for infection 
(Muilwijk et al., 2006; S. Ridgeway et al., 2005); it was not found to be an independent risk 
factor in the current analysis both before and after adjusting for other factors. 
It is not a common practice to include hospital characteristics in risk analysis models. An 
American study by R. S. Namba et al. (Namba et al., 2012 October), however, included hospital 
volume as one of the possible risk factors for surgical site infection, but no significant 
association between this factor and the risk of infection was found. In this study, both private 
hospitals and public hospitals that belonged to the Western Norway Regional Health Authority 
(Helse Vest RHF) showed lower risks of infection compared with hospitals belonged to the 
Middle/Central Norway Regional Health Authority (Helse Midt RHF). Additionally, compared 
to primary hospitals, the risk of developing surgical site infection for patients in specialty 
hospitals was significantly lower. These findings may indicate that there are considerable 
heterogeneities concerning the adherence to optimal guideline, surgeon experience, hospital 
infection control policy, etc. among different hospital regions and hospital types.  
Of all the risk factors for SSI, modifiable ones could be of interest for the design and 
implementation of preventive interventions to reduce infection rate. Based on the statistical 
results from the current study, perioperative antibiotic prophylaxis and cement fixation are 
recommended procedures for controlling SSIs. In Norway, however, they have been practicing 
for a long time (N. A. Register, 2015). This finding indicates that further studies in search of 
interventions to prevent SSI should focus on analyzing the effect of various parameters of 
perioperative antibiotic prophylaxis and cemented fixation, such as the time, route and dosage 
of administration, etc. 
It should be considered to include more surgery related and hospital related factors, such as 
primary diagnosis, skin preparation and bilateral procedures, in the NOIS dataset. It would be 
a helping hand in both estimating factor effect more accurately and establishing more practical 
and specific SSI prevention guidelines.  
5.1.2 Cost analysis 
The economic burden of SSI for Norwegian hospitals was high. The mean hospital cost of an 
SSI estimated in this study was NOK 198,121, incorporating a superficial infection cost of NOK 
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12,457 and deep or organ/space infection cost of NOK 407,487. Patients who developed an SSI 
on average spent 18 more days in hospital compared with those without infection, mainly due 
to readmission to hospital (15.2 days). The most important cost drivers for SSI identified in this 
study were subsequent inpatient stay (56%), revision surgery (28%) and prolonged initial length 
of stay (11%). The results of this study indicate that the additional cost for superficially infected 
patients was the result of prolonged stay in hospital and that for severely infected patients was 
largely due to revision procedure and re-hospitalization. These findings support the hypothesis 
regarding the cost drivers for SSI treatment. 
Since no study had examined the economic impact of SSI after hip arthroplasty for Norwegian 
hospitals before, direct comparison with other studies could not be carried out. Unlike the risk 
factor analysis, cost findings reported by previous researchers varied considerably due to 
inconsistencies in research methods, health care system settings, cost components included and 
perspectives adopted, etc. and one should be cautious about comparing them without any further 
analysis. 
A UK study (Jenks et al., 2014) yielded a median cost attributable to SSI following hip 
replacement of GBP 3,214 (NOK 43,235) while C. Edwards et al. (2008) claimed in their study 
that the mean cost for treating an infected patient was GBP 25,940 (NOK 419,853).  A plausible 
explanation for the huge difference in these two cost estimations could be the heterogeneity in 
infection severity, type of revision surgery and inclusion of readmission. 
The present study found that costs of the hospital days and treatment increase by more than 
NOK 243,000 when deep wound infection exists. This increase along with severity is in line 
with the findings from some previous studies (C. Edwards et al., 2008; Urban, 2006). Broex 
and colleagueas (Broex et al., 2009) reviewed a number of studies on SSIs to compare the 
magnitudes of costs due to SSI in 2009 and found that the cost of SSI was mainly due to 
prolonged length of stay (LOS). Peel and coworkers (Peel et al., 2013) reported a similar 
conclusion that duration of hospitalization was one of the most import contributors to SSI cost. 
This study identifies readmission (56%) as the most important cost driver, followed by 
reoperation (28%) and prolonged initial hospital stay (11%), therefore, confirming the previous 
findings.  
Results from this study indicates that two-stage revision is the most costly management strategy 
(NOK 603,486), followed by one-stage revision (NOK 351,856) and resection (NOK 295,880). 
Though cost estimates were lower, Australian researchers Merollini et al. (2013) reported a 
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similar cost pattern in their 2013 study. On the other hand, although in the same Australian 
settings, Peel T.N and colleagues (Peel et al., 2013) reported a total hospital cost for patients 
treated with one-stage revision of AUD 77,180 (NOK 473,573) and that for patients had 
arthroplasty resection of AUD 64,007 (NOK 392,722) and further identified one-stage 
exchange and resection arthroplasty as the indicators of increased cost. This, however, is not a 
finding that the present study results can support.  
An average cost of NOK 198,121 and an increasing risk of revision due to surgical site infection 
(Dale et al., 2009) in Norway imply that substantial cost savings can be achieved by reducing 
the number of SSIs. To reduce the number of SSIs, more risk factors are expected to be detected 
and preventive interventions are to be designed and implemented accordingly. Moreover, as a 
main cost driver, management strategies for SSI should be optimized to increase the success 
rate and minimize total cost. 
 
5.2 Limitations and strengths 
Compared to previous risk factor analysis based on smaller datasets (Dale, Skramm et al. 2011), 
the overall sample size from NOIS dataset was sufficient enough to allow for obtaining more 
statistically significant results. Additionally, the mandatory nature of NOIS, almost complete 
hospital participation and high completeness of 30-day follow-up have restrained selection bias 
to a minimal degree. 
However, like any research, there are limitations to this study and the results should be 
interpreted with caution. 
A general limitation of this study is associated with the observational nature of a retrospective 
study. Using observational data that is registered retrospectively means that only association, 
no causation, can be inferred. For instance, in this study, one can only conclude that infected 
patients stayed one day longer in hospital than non-infected patients did and assume there is 
correlation between infection and hospital stay. No statement like surgical site infection makes 
patient spend one more day in hospital can be made based on this dataset.  
The second limitation of this study is about the confounding effect. The number of risk factors 
included in this study was limited to those reported within the NOIS network. And variables 
included in the NOIS dataset were not complete, in a sense that data concerning potential 
confounders such as diabetes, preoperative diagnosis, etc. (Triantafyllopoulos et al., 2015) was 
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missing. Therefore, the confounding effect could not be completely disregarded although some 
well-known confounders had been adjusted for.  
The third limitation is related to not including 1-year patient follow-up in the analysis. 30-day 
follow-up is long enough for most procedures, but for those involve implanting, such as hip 
arthroplasty, 1-year may be a better choice for capturing more information about late surgical 
site infections.  
Costs in this study were estimated in great detail and the estimations covered a comprehensive 
list of relevant items. Besides, instead of taking from other countries all the unit costs were 
derived from local official dataset. Aside from these strengths, there are three main limitations 
in the cost analysis. 
Firstly, cost for SSI estimated in this study may have been overestimated by double counting 
the cost of readmission stay. By its definition, DRG reimbursement cost for revision surgery 
due to infection should have included the cost of inpatient stay during the “revision period”. 
Given this is the case, the cost of inpatient stay is supposed to be subtracted from the total 
reimbursement cost. However, lacking information about the proportion that inpatient stay cost 
constitutes in the reimbursement cost restricts the author from doing so. Another reason for 
potential cost overestimation lies in the health financing system. DRG reimbursement was 
assumed as the only way of financing hospitals in this study. In practice, however, only 50% of 
the hospital cost was funded through DRG system. According to a study comparing actual 
hospital cost with full DRG reimbursement for liver transplantation in Norway, full DRG 
reimbursement cost was higher than the actual cost. And this scenario is likely to happen in the 
study case as well. 
The end point of cost analysis was the complete of first revision procedure instead of patients 
recovering from surgical site infection. While in practice patients are likely to need more than 
one revision procedures to fully recover from SSI (Merollini et al., 2013). In this sense, the cost 
might be underestimated.  
With these two contradictory effects, it is extremely difficult to conclude whether the costs in 
this study has been overestimated, underestimated or not. 
The last limitation is related to the expert survey. Information obtained from survey cannot 
completely disregard recall bias and the representativeness of the only survey data remains to 
be examined. Due to low orthopedic response rate, the quantification of health care resources 
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was based on the only expert’s opinion. Such extremely small sample size could possibly 
introduce huge variation and uncertainty although the crucial data, such as subsequent hospital 
stay, was relatively comparable with other studies (Broex et al., 2009). The preplanned 
bootstrap of cost samples and the test for differences in costs across diagnoses could not be 
done without more survey data; therefore no variations in costs can be captured. These flaws 
brought by expert survey and small sample size indicate that using objective information and 
sufficient sample size are extremely important for an accurate estimation of SSI cost.  
6   Conclusion  
Of all the risk factors detected in this study, cemented prosthesis and perioperative antibiotic 
prophylaxis are the modifiable ones and therefore recommended to orthopedic surgeon and 
infection control personnel for controlling and reducing SSIs following THA. Given these two 
are common practice in Norway, further studies could focus on including more explanatory 
variables in risk analysis or on analyzing the effect of various parameters of perioperative 
antibiotic prophylaxis and cement fixation (such as the time, route and dosage of 
administration) to establish more effective preventive interventions. 
Surgical site infection following primary hip arthroplasty causes significant economic burde n 
for Norwegian hospitals, mainly due to substantial increase in hospital stay and the resource 
demanding nature of its revision procedures. The high cost of SSI implies that substantial cost 
savings can be achieved by reducing the number of SSIs, and in turn, highlights the importance 
of detecting modifiable risk factors for SSI. 
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Appendix 1 Regional health authority and its corresponding 
counties in Norway 
Health Region  Corresponding counties 
South-Eastern Regional Health Authority  
Østfold, Akershus, Oslo, Hedmark, Oppland, 
Buskerud, Vestfold, Telemark, Aust-Agder, Vest-
Agder 
Western Norway Regional Health Authority  Rogaland, Hordaland, Sogn og Fjordane 
Central Norway Regional Health Authority Møre og Romsdal, Sør-Trøndelag, Nord-Trøndelag 
Northern Norway Regional Health Authority  Nordland, Troms, Finnmark 
 
 
(Source: liv-lage.no) 
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Appendix 2 Expert survey of resource used after primary hip 
arthroplasty for non-infected patients 
 
  
Infeksjon etter primær total hofteprotese
Paientkarakteristika og utfall
Innleggelsen der totalprotese ble innsatt (Initial hospitalization)
Antall dager forlengelse av opphold (Number of days extension of stay) Dager: 3-7
Sårbehandling (Wound care) Type: Plaster Antall: 3
Rtg undersøkelser (X-ray investigation) Antall: 2
Antibiotika Type: Cefalotin Dose per dag: 2g X 4 Antall dagers behandling: 1
Blodkulturprøver Antall: 0
Bakteriologisk test fra sår Antall: 0
Behandling/kontroll hos fastlege/almenlege
Antall legebesøk Antall: 1
Sårbehandling Type: Fjerne sting Antall: 1
Blodprøver Antall: 0
Behandling/kontroll på sykehuspoliklinikk
Antall poliklinikkbesøk Antall: 4
Sårbehandling Type: Ingen Antall: 0
Rtg undersøkelser Antall: 4
Ultralydundersøkelser Type US 0 Antall:
Antibiotika (i tillegg til det som ble forskrevet i sykehus eller fastlege) Type: Ingen Dose per dag: 0 Antall dagers behandling: 0
Bakteriologisk test fra sår Antall: 0
Reinnleggelser i sykehus
Antall Antall: 0
Gjennomsnittlig varighet (average duration) Antall dager: 0
Antall poliklinikkbesøk Antall: 0
Sårbehandling Type: Ingen Antall:
Antibiotika (i tillegg til det som ble forskrevet i sykehus eller fastlege) Type: Ingen Dose per dag: Antall dagers behandling:
Reoperasjon Antall: Ingen
Utstyr/Protese brukt Type: Vanlig proteseAntall: 1
Bakteriologisk test fra sår Antall: 0
Blodprøver: Antall: 0
Ikke infisert
Som regel meget godt funksjonelt utfall, 15% medisinsk invaliditet (NAV tabell)
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Appendix 3 Expert survey of resource used after primary hip 
arthroplasty for patients treated with DAIR or 1-stage 
revision 
 
  
Infeksjon etter primær total hofteprotese
Paientkarakteristika og utfall
Innleggelsen der totalprotese ble innsatt (Initial hospitalization)
Antall dager forlengelse av opphold (Number of days extension of stay) Dager: 3-7
Sårbehandling (Wound care) Type: Plaster Antall: 3
Rtg undersøkelser (X-ray investigation) Antall: 2
Antibiotika Type: Cefalotin Dose per dag: 2g X 4 Antall dagers behandling: 1
Blodkulturprøver Antall: 0
Bakteriologisk test fra sår Antall: 0
Behandling/kontroll hos fastlege/almenlege
Antall legebesøk Antall: 8
Sårbehandling Type: Fjerne sting Antall: 1
Blodprøver Antall: 8
Behandling/kontroll på sykehuspoliklinikk
Antall poliklinikkbesøk Antall: 6
Sårbehandling Type: Ingen Antall: 0
Rtg undersøkelser Antall: 4
Ultralydundersøkelser Type US LeddpunksjonAntall: 1
Antibiotika (i tillegg til det som ble forskrevet i sykehus eller fastlege) Type: Se reinnl.
Bakteriologisk test fra sår Antall: 1
Reinnleggelser i sykehus
Antall Antall: 1
Gjennomsnittlig varighet (average duration) Antall dager: 14
Antall poliklinikkbesøk Antall: 3
Sårbehandling Type: Plaster Antall: 5
Antibiotika (i tillegg til det som ble forskrevet i sykehus eller fastlege) Type: Rimactan Dose per dag: 300mg x 2Antall dagers behandling: 90
Type: Vancomicin Dose per dag: 1g x 2 7
Ciproxin 750 mg x 2 83
Reoperasjon Antall: 1 Samlet varighet: 2 t
Utstyr/Protese brukt Type: Bytte hode og linerAntall: 1
Bakteriologisk test fra sår Antall: 5-8
Blodprøver: Antall: 14
Debridement og retensjon eller 1-trinns revisjon 
Som regel godt funksjonelt utfall, 25% medisinsk invaliditet (NAV tabell)
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Appendix 4 Expert survey of resource used after primary hip 
arthroplasty for patients treated with 2-stage revision 
 
  
Infeksjon etter primær total hofteprotese
Paientkarakteristika og utfall
Innleggelsen der totalprotese ble innsatt (Initial hospitalization)
Antall dager forlengelse av opphold (Number of days extension of stay) Dager: 3-7
Sårbehandling (Wound care) Type: Plaster Antall: 3
Rtg undersøkelser (X-ray investigation) Antall: 2
Antibiotika Type: Cefalotin Dose per dag: 2g X 4 Antall dagers behandling: 1
Blodkulturprøver Antall: 0
Bakteriologisk test fra sår Antall: 0
Behandling/kontroll hos fastlege/almenlege
Antall legebesøk Antall: 8
Sårbehandling Type: Fjerne sting Antall: 1
Blodprøver Antall: 8
Behandling/kontroll på sykehuspoliklinikk
Antall poliklinikkbesøk Antall: 8
Sårbehandling Type: Ingen Antall: 0
Rtg undersøkelser Antall: 4
Ultralydundersøkelser Type US LeddpunksjonAntall: 1
Antibiotika (i tillegg til det som ble forskrevet i sykehus eller fastlege) Type: Se reinnl
Bakteriologisk test fra sår Antall: 1
Reinnleggelser i sykehus
Antall Antall: 2
Gjennomsnittlig varighet (average duration) Antall dager: 21
Antall poliklinikkbesøk Antall: 6
Sårbehandling Type: Plaster Antall: 10
Antibiotika (i tillegg til det som ble forskrevet i sykehus eller fastlege) Type: Vancomicin Dose per dag: 1g x 2 Antall dagers behandling: 7
Ekvacillin 2g x 4 7
Diclocil 1g x 4 76
Reoperasjon Antall: 2 Samlet varighet: 5 t
Utstyr/Protese brukt Type: AntibiotikaspacerAntall: 1
Revisjons protese 1
Bakteriologisk test fra sår Antall: 10-16
Blodprøver: Antall: 20
2-trinns revisjon 
Brukbart funksjonelt resultat, 35% medisinsk invaliditet (NAV tabell)
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Appendix 5 Expert survey of resource used after primary hip 
arthroplasty for patients treated with prosthesis resection 
   
Infeksjon etter primær total hofteprotese
Paientkarakteristika og utfall
Innleggelsen der totalprotese ble innsatt (Initial hospitalization)
Antall dager forlengelse av opphold (Number of days extension of stay) Dager: 3-7
Sårbehandling (Wound care) Type: Plaster Antall: 3
Rtg undersøkelser (X-ray investigation) Antall: 2
Antibiotika Type: Cefalotin Dose per dag: 2g X 4 Antall dagers behandling: 1
Blodkulturprøver Antall: 0
Bakteriologisk test fra sår Antall: 0
Behandling/kontroll hos fastlege/almenlege
Antall legebesøk Antall: 8
Sårbehandling Type: Fjerne sting Antall: 1
Blodprøver 8
Behandling/kontroll på sykehuspoliklinikk
Antall poliklinikkbesøk Antall: 4
Sårbehandling Type: Ingen Antall: 0
Rtg undersøkelser Antall: 2
Ultralydundersøkelser Type US Ledpunksjon Antall: 1
Antibiotika (i tillegg til det som ble forskrevet i sykehus eller fastlege) Type: Se reinnl
Bakteriologisk test fra sår Antall: 1
Reinnleggelser i sykehus
Antall Antall: 1
Gjennomsnittlig varighet (average duration) Antall dager: 14
Antall poliklinikkbesøk Antall: 3
Sårbehandling Type: Plaster Antall: 10
Antibiotika (i tillegg til det som ble forskrevet i sykehus eller fastlege) Type: Vancomicin Dose per dag: 1g x 2 Antall dagers behandling: 7
Ekvacillin 2g x 4 7
Diclocil 1g x 4 28
Reoperasjon Antall: 1 Samlet varighet: 3 t
Utstyr/Protese brukt Type: Fjerne protese
Bakteriologisk test fra sår Antall: 5-8
Blodprøver: Antall: 14
Reseksjon 
Gamle og syke pasienter, dårlig funksjonelt resultat, 45% medisinsk invaliditet (NAV tabell)
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Appendix 6 Wound contamination classification  
Wound contamination 
Class Definition 
 I 
Clean surgical wounds show no signs of inflammation and do not involve the 
respiratory, gastrointestinal or genitourinary tracts. Laparoscopic surgeries, 
surgeries involving the skin (such as biopsies), eye or vascular surgeries are 
good examples. 
  
  
  
  
  
 II 
Clean-contaminated wounds are clean wounds with a higher risk of 
infection such as those involving the gastrointestinal, respiratory or 
genitourinary tracts, as long as the surgery is uncomplicated. Any wound 
opened to remove pins or wires, chest procedures, ear surgeries or 
gynecologic procedures are considered class II surgical wounds. 
  
  
  
  
  
  
 III  
 Contaminated wounds are created when an outside object comes in 
contact with the wound. This could be a bullet, knife blade or other pointy 
object. Or the contamination could be caused by large amounts of spillage 
from the GI tract into the wound. Any highly inflamed or infected tissue 
around a surgical wound is considered contaminated. 
  
  
  
  
  
  
 IV 
Dirty-infected surgical wounds include those with a foreign object lodged in 
the wound (such as a bullet or other debris). This class also includes 
traumatic wounds from a dirty source where the treatment was delayed, 
infected surgical wounds or any wound that has been exposed to pus or 
fecal matter. 
  
  
  
  
  
  
 
 
 
